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ABSTRACT 
Recent advances in the field of cancer immunotherapy have enabled this therapeutic 
approach to enter the mainstream of modern cancer treatment. In particular, adoptive 
T cell therapy (ACT) is a potentially powerful immunotherapy approach that relies on 
the administration of tumor-specific T cells into the patient. There are several 
strategies to obtain tumor-reactive cytotoxic T lymphocytes (CTLs), which have 
already been shown to induce remarkable responses in the clinical setting. However, 
there are concerns and limitations regarding the conventional approaches to obtain 
tumor-reactive T cells, such as accuracy of procedure and reproducibility. Therefore, 
we aimed to develop two approaches to improve the precision and efficacy of tumor-
reactive T cells therapy. These two techniques could constitute effective, safe and 
broadly applicable alternatives to the conventional methods for obtaining tumor-
specific CTLs. 
The first approach of this study is the so called “Doublet Technology”. Here, we 
demonstrate that peptide-human leukocyte antigen-T cell receptor (pHLA-TCR) 
interactions that involve immune reactive peptides are stable and strong. Therefore, 
the CTLs that are bound by their TCR to tumor cells can be selected and isolated 
through FACS-based cell sorting taking advantage of this stable interaction between 
the CTLs and the target cells. The CTLs from acute myeloid leukemia (AML) patients 
obtained with this technique show cytolytic activity against blast cells suggesting a 
potential clinical use of these CTLs. “Doublet Technology” offers a personalized 
therapy in which there is no need for a priori knowledge of the exact tumor antigen. 
The second approach of this study is the Chimeric Antigen Receptor (CAR) 
Technology. We design several CARs targeting the B-Cell Maturation Antigen 
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(BCMA). BCMA CAR T cells show antigen-specific cytolytic activity, production of 
cytokines including IFN-γ and IL-2, as well as productive proliferation. Although we 
confirm the presence of soluble BCMA in serum of multiple myeloma (MM) patients, 
we demonstrate that the presence of soluble protein does not abrogate the efficacy 
of BCMA CAR T cells suggesting that BCMA CAR T cells can be used in the clinical 
setting to treat MM patients. The high antigen specificity of CAR T cells allows 
efficient tumor cell eradication and makes CAR Technology attractive for broadly 
applicable therapies. 
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RESUMEN 
Los recientes avances en el campo de la inmunoterapia contra el cáncer han hecho 
posible que dicha técnica se convierta en uno de los principales tratamientos del 
cáncer en la actualidad. En particular, la terapia adoptiva de células T (ACT, por sus 
siglas en inglés) es un enfoque potencialmente poderoso que se basa en la 
administración al paciente de células T específicas de tumor. Existen varias 
estrategias para obtener linfocitos T citotóxicos (CTL, por sus siglas en inglés) 
reactivos frente a tumor, los cuales han demostrado inducir notables respuestas en 
el contexto clínico. Sin embargo, existen limitaciones con respecto a los enfoques 
convencionales para obtener células T reactivas frente a tumor, tales como la 
precisión del procedimiento y la reproducibilidad. Con el fin de abordar estas 
cuestiones, desarrollamos dos técnicas para mejorar la precisión y la eficacia de la 
terapia con células T reactivas frente a tumor. Dichas técnicas podrían constituir 
alternativas eficaces, seguras y ampliamente aplicables a los métodos 
convencionales para la obtención de CTLs anti-tumorales.  
El primer enfoque de este estudio es la llamada "Tecnología de Dobletes". En este 
caso, demostramos que las interacciones péptido-antígeno leucocitario humano-
receptor de células T (pHLA-TCR) que implican péptidos inmuno-reactivos son 
estables y fuertes. Por lo que, los CTLs unidos a través de TCR a las células 
tumorales pueden ser seleccionados y aislados mediante separación celular basada 
en citometría aprovechando la interacción estable entre los CTLs y las células diana. 
Los CTLs de pacientes con leucemia mieloide aguda (LMA) obtenidos mediante esta 
técnica muestran actividad citolítica contra células blásticas, lo que sugiere el 
potencial uso clínico de estos CTLs. La “Tecnologia de Dobletes” ofrece una terapia 
personalizada en la que no es necesario conocer a priori el antígeno tumoral. 
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El segundo enfoque de este estudio es la tecnología de receptores de antígenos 
quiméricos (CAR, por sus siglas en ingles). Diseñamos varios CARs dirigidos frente 
al antígeno de maduración de células B (BCMA, por sus siglas en ingles). Las 
células T BCMA CAR muestran actividad citolítica específica de antígeno, 
producción de citoquinas incluyendo IFN-γ e IL-2, así como, capacidad proliferativa. 
Aunque confirmamos la presencia de BCMA soluble en suero de pacientes con 
mieloma múltiple (MM), demostramos que la presencia de proteína soluble no anula 
la eficacia de las células T BCMA CAR, lo que sugiere que dichas células pueden 
ser utilizadas en el contexto clínico para tratar el MM. La alta especificidad antigénica 
de las células T CAR permite una erradicación eficaz de las células tumorales y hace 
que la Tecnología CAR sea un tratamiento atractivo y ampliamente aplicable. 
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ZUSAMMENFASSUNG  
Durch jüngste Fortschritte auf dem Gebiet der Krebsimmuntherapie konnte dieser 
therapeutische Ansatz in der Mitte moderner Krebsbehandlungen ankommen. 
Insbesondere die adoptive T-Zelltherapie (ACT), die auf der Verabreichung 
tumorspezifischer T-Zellen an den Patienten beruht, stellt einen potentiell 
schlagkräftigen immuntherapeutischen Ansatz dar. Es existieren bereits 
verschiedene Strategien um tumorreaktive zytotoxische T-Lymphozyten (CTL) 
herzustellen, von denen bereits gezeigt wurde, dass sie klinisch bemerkenswerte 
Antworten hervorrufen. Dennoch gibt es Bedenken und Grenzen bezüglich dieser 
konventionellen Ansätze zur Herstellung tumorreaktiver T-Zellen, wie zum Beispiel 
die Genauigkeit und Reproduzierbarkeit des Verfahrens. Daher arbeiteten wir an der 
Entwicklung zweier Ansätze um die Präzision und Effizienz der tumorreaktiven T-
Zelltherapie zu verbessern. Diese beiden Techniken könnten effektive, sichere und 
breit anwendbare Alternativen zu den konventionellen Methoden der 
tumorspezifischen CTL-Gewinnung darstellen. 
Der erste Ansatz dieser Studie wird als „Doublet Technology“ bezeichnet. Hierbei 
zeigen wir, dass die Interaktionen zwischen Peptid/MHC-Komplex und T-Zellrezeptor 
(pHLA-TCR), die immunreaktive Peptide involvieren, stabil und solide sind. 
Außerdem zeigen wir, dass CTLs, die über ihren TCR an Tumorzellen gebunden 
sind, selektioniert und durch FACS-basierte Zellsortierung isoliert werden können. 
Hierbei wird die Stabilität der Interaktion von CTLs und Zielzellen genutzt. Die CTLs 
von Patienten mit Akuter Myeloischer Leukämie (AML), die auf diese Weise 
gewonnen werden, zeigen zytolytische Aktivität gegenüber Blasten, was auf einen 
potentiellen klinischen Nutzen dieser CTLs hinweisen könnte. Die „Doublet 
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Technology“ bietet eine personalisierte Therapie, die kein vorheriges Wissen über ein 
exaktes Tumorantigen erfordert. 
Der zweite Ansatz dieser Studie ist die Chimere Antigenrezeptor (CAR) Technologie. 
Wir entwickeln verschiedene CARs gegen das B-Zellmaturationsantigen (BCMA). 
BCMA-CAR T-Zellen zeigen antigenspezifische zytolytische Aktivität, Produktion der 
Zytokine IFN-γ und IL-2 sowie produktive Proliferation. Obwohl wir bestätigen, dass 
lösliches BCMA im Serum von Multiplen Myelompatienten zu finden ist, zeigen wir 
auch, dass dieses lösliche Protein nicht die Effizienz von BCMA-CAR T-Zellen 
beeinträchtigt und somit BCMA-CAR T-Zellen zur Behandlung von Multiplen 
Myelompatienten klinisch genutzt werden können. Die hohe Antigenspezifität der 
CAR-T-Zellen erlaubt eine effiziente Vernichtung von Tumorzellen und macht die 
CAR-Technologie attraktiv für breit einsetzbare Therapien. 
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1. Adoptive T Cell Immunotherapy for Cancer 
Cancer remains the major devastating disease throughout the world, with 
approximately 14 million new cases and 8.2 million cancer related deaths in 2012. 
The number of new cases is expected to rise by about 70% over the next 2 decades. 
Globally, nearly 1 in 6 deaths is due to cancer (McGuire, 2016).  
Historically, there have been three pillars of cancer treatment: surgery, 
chemotherapy, and radiotherapy. Although these conventional therapies are often 
active in eliminating tumor cells, they are associated with toxic side effects and 
require extensive care and extended treatments. In recent years, immunotherapy has 
emerged as a possible fourth pillar, targeting cancer not by its anatomic location or 
propensity to divide, but by utilization of the inherent mechanisms used by the 
immune system to distinguish between healthy and pathologic tissue (Perica et al., 
2015). Immunotherapy approaches include the use of immune modulators, immune 
checkpoint blockade antibodies and cancer vaccines capable to boost the immune 
system and T cells. However, variable tumor regression is achieved in the majority of 
cancers (Rosenberg et al., 2008). Adoptive T cell therapy (ACT) is a potentially 
powerful immunotherapeutic approach to cancer treatment that relies on the infusion 
of tumor-specific T cells into the patient. From a theoretical standpoint, cancer 
immunotherapy using T cells has long been recognized as a promising approach. 
The ability of the immune system to recognize and eradicate cancer is well 
established (Kolb et al., 1995; Kolb, 2008). Adaptive immunity has numerous 
beneficial properties that make it amenable for cancer treatment: 1) T cell responses 
are specific, and can thus potentially distinguish between healthy and cancerous 
tissue; 2) T cells responses are robust, undergoing up to 1,000-fold clonal expansion 
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after activation; 3) T cells can traffic to the site of antigen presentation, suggesting a 
mechanism for eradication of distant metastases; and 4) T cell responses have 
memory, maintaining therapeutic effect for many years after initial treatment (Perica 
et al., 2015). 
While the mechanism of action was not initially understood, allogeneic hematopoietic 
stem cell transplantation (HSCT) for hematological malignancies represents the 
earliest adoptive transfer of T cells with anti-cancer activity (Welniak et al., 2007). 
Rather than simply replacing leukemic bone marrow with a healthy transplant, donor 
cells mediate a graft-versus-tumor effect against allogeneic antigens present on 
leukemic cells (Fabre, 2001), which reduces tumor burden and recurrence (Kolb et 
al., 1995). Unfortunately, lack of specificity in the allogeneic responses makes it 
challenging to separate the graft effect on tumor from the graft effect on host. 
Nowadays, the advanced knowledge of immunology, genetic engineering and cell 
culture has made it possible to enhance anti-tumor specificity and functionality of T 
cells. 
The most avant-garde approaches to obtain tumor-reactive T cells are harvesting and 
expanding tumor infiltrating lymphocytes (TILs) with endogenous tumor associated 
antigen T cell receptor (TCR) specificity, and genetic modification of T cells with 
either an engineered TCR, or a chimeric antigen receptor (CAR) (Figure 1) (Smith et 
al., 2014; Papaioannou et al., 2016). 
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Figure 1. The process of adoptive T cell immunotherapy. 
T cells are harvested either from tumor (TILs) or peripheral blood (peripheral blood 
lymphocytes, PBLs). TILs can be expanded non-specifically since they are preferentially 
tumor-specific prior to culture. In contrast, tumor specificity must be induced in PBLs, through 
genetic engineering. After several weeks of expansion in culture, tumor-specific T cells can 
be reinfused into the cancer patient (modified from (Perica et al., 2015). 
 
Cancer immunotherapy with tumor-reactive T cells has shown remarkable responses 
in patients (Rosenberg et al., 2008; Turtle et al., 2016). Although each type of ex-vivo 
modification of T cells has its different strengths and limitations (Figure 2), a single 
infusion might be sufficient to not only confer therapeutic anti-tumor effects, but also 
to cause life-long protection from relapse, even in patients where conventional 
treatment has failed or is no longer effective (Rosenberg et al., 2008; Curran et al., 
2012).  
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Figure 2. Adoptive T-cell therapies.  
Strengths and limitations of ACT therapies. HLA, human leukocyte antigen (Smith et al., 
2014). 
 
Consequently, cancer immunotherapy with tumor-reactive T cells is investigated as a 
novel treatment modality in patients with hematologic malignancies and solid tumors 
(Rosenberg et al., 2008; Curran et al., 2012; Restifo et al., 2012; Maude et al., 2014; 
Turtle et al., 2016).  
In this study, we aimed to develop two approaches for obtaining tumor-reactive T 
cells for clinical implementation in cancer immunotherapy of hematological 
malignancies. 
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2. Cytotoxic T Lymphocytes and Recognition of Tumor Antigens 
The advance in the knowledge of immunology over the last 20 years has been a key 
issue to understand the molecular-level of the interplay between the T lymphocyte 
and the malignant cell that results in cytotoxic suppression of the malignancy.  
The cytotoxic T lymphocytes (CTLs) are lymphocytes that kill target cells expressing 
target antigen in class I major histocompatibility complex (MHC-I) restricted manner. 
They are generally CD8+ T cells and play an effector role in the host response to 
virus-infected cells, organ transplants and tumor cells. Regarding tumor response, 
CTLs have the capacity to lysis tumor cells in an antigen-specific manner. Activation 
begins when receptors on the surface of T cells (TCR) recognize and bind to 
antigens or peptide fragments that are bound to MHC-I molecules, which are 
presented on the surface of specialized antigen presenting cells (APC) such as the 
dendritic cells (DC). The activation also requires the presence of co-stimulatory 
molecules. Once T cells are activated, there is recruitment of T helper cells that 
secrete cytokines such as interleukin-2 (IL-2) and granulocyte-macrophage colony-
stimulating factor (GM-CSF), which further enhances T cell activation and 
proliferation (Figure 3) (Kumar, 2012). 
Tumor cell recognition occurs when an activated CTL ligates through TCR its antigen 
on the tumor. If the avidity of the TCR to the antigen is sufficient, costimulatory 
molecules engage with ligands on the tumor cell and an immune synapse is formed 
between the T cell and its target, binding the two cells together and mediating the 
delivery of cytotoxic molecules into the tumor cell, leading to cell lysis by perforin and 
apoptosis by granzymes. Although CD4+ T cells are classically viewed as helper 
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cells facilitating CD8+ T cell function, it is now clear that both cell subsets can exert 
cytotoxicity against tumor targets (Restifo et al., 2012; Bollard and Barrett, 2014). 
 
Figure 3. Antitumor immune response. 
DCs capture antigens released by cancer cells. After intracellular processing, antigenic 
peptides are loaded onto MHC molecules on the surface of the DC. Specific T cells 
encounter these MHC-peptide complexes in conjunction with a co-stimulatory signal. The 
activated T cells proliferate and secrete cytokines (Kumar, 2012). 
 
This idealized picture of T cell mediated toxicity is modified by factors involving the 
functionality of CTL, the tumor target, and the milieu in which the interaction occurs. 
These considerations are important in the successful generation and administration 
of functional tumor-specific T cells to the patient (Kershaw et al., 2013; Perica et al., 
2015). Regarding functionality, CTL function is dependent on the maturational state 
of the effector cell. To expand into clones of effector cells, T cells must engage with 
their cognate antigen presented by an APC expressing the appropriate costimulatory 
molecules. DCs represent the most efficient type of APC for this purpose. 
Manufacturing of CTL in the laboratory include standard approaches based on the 
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use of DCs generated from CD34 cells or CD14 monocytes. As T cells expand, they 
generally acquire CD45RO and lose CD45RA surface molecules. Other factors 
affecting CTLs include cell subpopulations that suppress T-cell proliferation and 
function, chiefly regulatory T cells (Tregs) and myeloid-derived suppressor cells 
(MDSCs) (Restifo et al., 2012; Bollard and Barrett, 2014). 
Many tumors are immunogenic and provoke a host immune response, but this is 
normally not sufficient to overcome host tolerance or tumor microenvironment. For 
decades now, researchers have tried to develop new methods to enhance host 
immunological responses against tumor such as the infusion of tumor-specific T 
lymphocytes. 
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3. Conventional Methods for Obtaining Tumor-Specific CTLs 
Adoptive transfer of tumor-reactive cytotoxic T cells is a promising therapeutic 
approach for cancer treatment. To develop this strategy, it is necessary to isolate 
specific leukocyte subpopulations from peripheral blood or tumor tissue that will be 
reinfused into the patient after expansion in vitro. 
 
Two approaches are widely applied for the detection and isolation of antigen-specific 
cytotoxic T lymphocytes: 
The first is based on the assessment of specific T cells functions, such as cytokine 
(typically IFN-γ) production (Manz et al., 1995; Becker et al., 2001) or activation-
induced phenotypical alterations, such as cell surface expression of CD107a (LAMP-
1) and CD137 (4-1BB) (Rubio et al., 2003). IFN-γ production is the most commonly 
used variable to detect T-cell reactivity against antigen-presenting targets. However, 
cytokine-producing CD8+ T cells are not exclusively cytotoxic (Panelli et al., 2000; 
Snyder et al., 2003), and consequently in the therapeutic context, it is important to 
distinguish T-cell reactivity from ‘‘functional cytotoxicity,’’ specifically the capacity of 
CTLs to destroy target cells.  
An alternative strategy uses soluble pMHC multimers to detect and separate antigen-
specific T cells from the whole lymphocyte population. pMHC multimers consist of 
multiple pMHC complexes that have been chemically linked together and conjugated 
to a detectable marker (Wooldridge et al., 2009). Although, this technology has been 
successfully used (Cobbold et al., 2005; Savage et al., 2007), there are several 
obstacles that need to be solved. For example, the binding affinity threshold for 
pMHC class I (pMHC-I) tetramers is significantly higher than that required for T cell 
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activation. As a result, pMHC-I tetramers can often fail to stain antigen specific T cells 
where the interaction between pMHC and TCR is weaker than KD = 80 μM. Such 
pMHC-TCR affinities are not usually characteristic of CD8+ T cells specific for 
foreign, pathogen-derived antigens, and pMHC-I tetramers have excelled when used 
to characterize virus-specific cytotoxic T lymphocyte (CTL) populations. In contrast, 
the use of pMHC-I tetramers can be more problematic when the reagents are used to 
identify T cells specific for self-derived peptides (anti-tumor). Thus, at present, 
pMHC-I tetramers cannot be used to detect all antigen-specific CD8+ T cells 
(Wooldridge et al., 2009; Dolton et al., 2014). In addition, the use of MHC class II-
based reagents to obtain antigen-specific CD4+ T cells is still challenging. The lower 
affinity of pMHC-II-TCR interactions combines with the fact that the CD4 co-receptor 
does not contribute to pMHC-II-TCR stabilization to ensure that the average CD4+ T 
cell is almost 50-fold more difficult to stain with pMHC tetramers than the average 
CD8+ T cell (Hackett and Sharma, 2002; Wooldridge et al., 2009). Thus, there is a 
currently a pressing need to extend pMHC multimer technology to a point where it 
can be used to stain all antigen-specific T cells in all biological systems.  
In conclusion, both approaches have been used for obtaining tumor-specific CTLs, 
but there are still some limitations that need to be addressed. We present in this 
study two different approaches to obtain tumor-reactive T cells to treat hematologic 
malignancies: (1) a new method to select and isolate natural autologous tumor-
specific T cells from patients based on cell sorting; and (2) a novel procedure to 
engineer T cells with tumor-specific chimeric antigen receptors (CAR). 
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4. The T Cell-Tumor Cell Interaction 
The specificity of T cell activation clearly depends on the interaction of peptide-MHC 
(pMHC) complexes and TCR (van der Merwe, 2001). Other signals via coreceptors 
such as CD4 and CD8 or costimulatory interactions such as CD28 and CD80/CD86 
appear to act as amplifiers that increase the magnitude and/or duration of the TCR 
signals, but do not act independently. 
A kinetic model has been proposed that states that T cell signaling is highly 
dependent on the dissociation rate of pMHC from TCR. In this model, pMHC-TCR 
complexes with slow dissociation rates send positive signals to T cell, whereas fast 
off-rates result in negative signaling (McKeithan, 1995; Rabinowitz et al., 1996). This 
model explains the experimentally observed relationship between T cell function and 
dissociation rate of ligand from receptor in some reports (Matsui et al., 1994; Lyons et 
al., 1996; Kersh et al., 1998; Rosette et al., 2001; Krogsgaard et al., 2003; Qi et al., 
2006).  
Ding et al. were one of the first groups to show a correlation between the half-life of 
pMHC-TCR complexes and the type of functional signal generated by T cell. Thus, 
complexes pMHC-TCR with low dissociation constant (KD ) show specific lysis while 
complexes with high KD do not present this ability suggesting that long pMHC-TCR 
half-lives correlate tightly with agonist signals that induce T cell activation.(Ding et al., 
1999).   
More recently, it has been reported that presentation of low-, medium- and high-
potency pMHC complexes expressed by DCs in vivo leads to upregulation of T cell 
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activation markers, but only high-potency pMHC complexes induce considerable T 
cell proliferation and production of IFN-γ (Skokos et al., 2007).  
To study the strength of the pMHC-TCR interaction, we performed molecular 
dynamics simulations. The model system chosen was the well-defined human A6 
TCR which is specific to the TAX oligopeptide (LLFGYPVYV) of the human T cell 
lymphotropic virus HTLV-1 bound to the human class I MHC molecule HLA-A2 
responsible to cause adult T-cell leukemia/lymphoma (Garboczi et al., 1996). The 
TAX peptide is a strong agonist that induces T-cell activation at very low 
concentrations. Single mutations on TAX inhibit T-cell function instead of triggering it. 
The interactions of three peptide variants (P6A, V7R and Y8A) of TAX bound to HLA-
A2 with the A6 T cell receptor have been extensively studied using T cell assays, 
kinetic and thermodynamic measurements, and X-ray Diffraction (XRD). The V7R 
mutant weakly reacts and elicits the distinct cell responses at concentrations two 
orders of magnitude higher than TAX. The P6A and V8A species can be considered 
unreactive, as they barely induce any response at concentrations several orders of 
magnitude higher than those at which the response to wild-type species saturates 
(Ding et al., 1998; Ding et al., 1999). 
Altogether, these studies prompt us to hypothesize that tumor-reactive T cells may 
form strong interactions with tumor cells so that they could be identified and isolated 
by FACS-based cell sorting to pull out naturally occurring tumor-specific T cells in 
hematologic malignancies. 
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5. Tumor-Infiltrating Lymphocyte Therapy 
It was convincingly shown that tumor-infiltrating lymphocytes (TILs) selected for 
reactivity towards autologous melanoma cells displayed high functional activity in 
metastatic melanoma patients. The earliest trials of ACT using TILs isolated from 
cancer samples were conducted at the surgical branch of the National Cancer 
Institute (NCI) in Bethesda, Maryland, USA in 1988 (Rosenberg et al., 1988). 
Objective response rates (ORR) by Response Evaluation Criteria In Solid Tumors 
(RECIST) criteria were observed in 11 of 20 patients with metastatic melanoma, and 
in 34% of patients of a larger follow-up report in 1994 (Rosenberg et al., 1994). 
Unfortunately, only 5 of the 29 responses were complete, and the median duration of 
response in these early studies was only 4 months. 
A major breakthrough occurred with the addition of lymphodepletion prior to ACT 
(Figure 4). The benefits of total body irradiation and lymphodepleting chemo-therapy 
were first illustrated in mouse models of B16 melanoma (Gattinoni et al., 2005). The 
addition of lymphodepletion increased response rates in stage IV melanoma patients 
to 49%, 52%, and 72% with three sequential protocols of increasing intensity total 
body irradiation (Rosenberg et al., 2011; Geukes Foppen et al., 2015). Complete 
responses were achieved in 20 of 93 patients treated, and 19 of these 20 responses 
have persisted for at least 5 years. Comparable results have now been achieved 
outside of the NCI, as shown by a clinical trial that utilized a lymphodepleting 
chemotherapy regimen with no total body irradiation leading to a response rate of 
48% (4 complete, 11 partial) (Besser et al., 2010; Itzhaki et al., 2011).  
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Figure 4. Isolation of TIL and expansion of tumor-specific T cell populations.  
Tumors are often complex masses containing diverse cell types. These masses can be 
surgically resected and fragmented, and the cells can be placed in wells into which a T cell 
growth factor, such as interleukin-2 (IL-2), is added. T cell populations that have the desired 
T cell receptor (TCR) specificity can be selected and expanded, and then adoptively 
transferred into patients with cancer. Prior to this adoptive transfer, hosts can be 
immunodepleted by either chemotherapy alone or chemotherapy in combination with total-
body irradiation. The combination of a lymphodepleting preparative regimen, adoptive cell 
transfer and a T cell growth factor can lead to prolonged tumor eradication in patients with 
metastatic melanoma. MDSC, myeloid-derived suppressor cell; NK, natural killer; TReg, 
regulatory T (Geukes Foppen et al., 2015). 
 
Several works have already shown new protocols to generate TILs. For example, in 
2010 the ﬁrst clinical trial, in which patients with metastatic melanoma were treated 
with TIL leaving out the selection step and also including a CD8 enrichment step, was 
reported (Dudley et al., 2010). This was considered because of the risk of 
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contamination with regulatory T lymphocytes (Tregs) which might in turn be infused 
as well, if bulk TIL were given. In this trial, 56 patients could be treated and the ORR 
for all treated patients was 54%.  
TIL therapy is now explored in other cancers than melanoma, demonstrating that this 
approach is both feasible and efﬁcacious. Prior work has shown that out of nine 
patients with metastatic cervical cancer treated with TIL therapy, three patients 
experienced an OR including two patients with complete tumor regression lasting 
over one year (Stevanovic et al., 2015). Moreover, a recent article characterized TILs 
obtained from head and neck cancer metastases. TILs were expanded with high 
efﬁciency (80% of patients, with massive expansion for up to 3500 folds), and 
recognition of tumor antigens could be demonstrated in 60% of patients (Junker et 
al., 2011). More recently, the first report of successful treatment of a patient with 
epithelial cancer (cholangiocarcinoma) was reported. Whole-exome sequencing of 
the patient´s tumor was used to identify a mutation in erbb2 (HER2) that was 
recognized by a small subset of TIL. Subsequent expansion and reinfusion of mutant 
specific TIL resulted in dose-dependent durable clinical responses (Smith et al., 
2014; Tran et al., 2014).  
TIL therapy clearly demonstrates success in solid tumors; however, further work is 
needed to isolate tumor-reactive T cells in other cancers like hematologic 
malignancies. In fact, it has been recently reported that marrow-infiltrating 
lymphocytes (MILs) could be used to treat myeloma patients (Borrello and Noonan, 
2016). In this sense, the first aim of this study was to develop a new procedure to 
identify and isolate anti-tumor T lymphocytes (“like TILs”) from acute myeloid 
leukemia (AML) patients.    
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6. Gene-Modified T Cell Therapy 
A significant advance in the field of ACT is the ability to confer to the T cells 
specificity for tumor antigens or tumor cell surface molecules by the introduction of 
genes that encode high affinity tumor-targeting T cell receptors (TCRs) or synthetic 
chimeric antigen receptors (CARs) respectively (Riddell et al., 2014). 
In the era of personalized medicine, T cells or defined T cell subsets with distinct 
functional attributes can be isolated from patient blood and genetically modified to 
express a transgene encoding a tumor targeting TCR or CAR. The genetically 
modified T cells are then expanded in vitro and if necessary, enriched before infusion 
into the patient. Conditioning chemoradiotherapy may be administered to the patient 
to induce lymphodepletion prior to T cell infusion in order to enhance the persistence 
of infused T cells. Figure 5 depicts an example of a general strategy for engineering 
autologous T cells for adoptive immunotherapy (Turtle et al., 2012).  
Genes encoding TCRs can be isolated from high avidity T cells that recognize cancer 
antigens and retroviral or lentiviral vectors can be used to redirect lymphocyte 
specificity to these cancer antigens (Rosenberg et al., 2008). TCR gene transfer 
provides a mechanism to generate large numbers of autologous T cells directed 
against epitopes from intracellular tumor-specific antigens presented on MHC. The 
best clinical example of TCR gene transfer therapy targeted the cancer/testis antigen 
NY-ESO-1 in patients with melanoma. Overall, nine out of 17 patients had objective 
clinical responses with two out of 11 melanoma patients achieving a complete 
remission lasting more than 1 year (Robbins et al., 2011). Other targets have shown 
less efficacy, such as melanoma antigen recognized by T-cells 1 (MART1) (Morgan 
et al., 2006). Several others have been highly toxic, such as carcinoembryonic 
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antigen (Parkhurst et al., 2011), and affinity enhanced MAGE-A3, which resulted in 
surprising off-target cytotoxicity (Linette et al., 2013; Morgan et al., 2013).  
 
Figure 5. Schema for adoptive immunotherapy with genetically modified T cells. 
T cells are isolated from peripheral blood mononuclear cells (PBMC) of patients and 
transduced with TCR or CAR transgenes. These cells are expanded ex vivo and then 
reinfused into the same patient. Lymphodepletion conditioning is needed before gene 
modified T cells infusion (Turtle et al., 2012). 
 
Additional studies are needed to address not only expected technical issues such as 
the necessity of unique TCRs for different human leukocyte antigen (HLA) types, or 
potential mispairing of TCR α/β chains, but also unfavorable efficacy:toxicity ratios 
seen in several early trials from molecular mimicry and ‘off-target’ cytotoxicity (Turtle 
et al., 2012; Smith et al., 2014). This has led to a current focus on the genetic 
modification of T cells with CARs.  
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7.  CAR Design and Mode of Action 
Chimeric antigen receptors (CAR) are synthetic receptors that link the antigen 
specificity of a monoclonal antibody (mAb) to the killing and proliferation capabilities 
of T cells. CARs are comprised of an extracellular domain derived from single-chain 
variable fragment (scFv) of a mAb, which serves as the antigen binding moiety. The 
extracellular spacer domain provides flexibility and reach for antigen binding. A 
transmembrane (TM) domain links the extracellular domain to an intracellular 
signaling/activation module, most commonly composed of a T cell receptor (TCR)-
derived CD3ζ chain and one or more co-stimulatory domains such as CD28 or 4-1BB 
(Figure 6).  
 
Figure 6: CAR design.  
Chimeric antigen receptors (CARs) are composed of a single-chain antibody variable 
fragment (scFv) extracellular domain linked through hinge and transmembrane domains 
(represented in the figure by CD8) to a cytoplasmic signaling region that was derived from 
CD3ζ. Gene encoding the scFv is derived from a B cell that produces a tumor-specific 
antibody (modified from (Kershaw et al., 2013). 
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Compared with natural TCRs, CARs have several orders of magnitude higher 
affinities to target antigens that make them more potent in tumor eradication (Harris 
and Kranz, 2016). In addition, CARs recognize intact cell surface proteins in an MHC-
independent manner. Therefore, most of the CAR-based approaches are insensitive 
to tumor escape mechanisms related to MHC loss variants (Zhou and Levitsky, 
2012). Moreover, CAR therapy bypasses many other mechanisms through which 
cancer cells escape immunorecognition. These mechanisms include reduced 
expression of costimulatory molecules, induction of suppressive cytokines and 
recruitment of regulatory T cells (Han et al., 2013). In addition, they can be used in all 
individuals regardless of their human leukocyte antigen (HLA) type, which is a distinct 
advantage over TCRs. However, in contrast to natural TCRs, CARs only detect 
antigens that are expressed on the surface of tumor cells. Nonetheless, most tumor 
types can be targeted using CARs (Kershaw et al., 2013). 
Construction of a CAR relies on the identification of a suitable antibody which binds 
to a cell surface molecule of interest. Because CAR recognition does not rely on 
peptide processing or presentation by MHC, the number of target epitopes is 
stoichiometrically equal to the number of target antigen molecules on the cell surface, 
and every surface expressed target molecule represents a potential CAR-triggering 
epitope, contributing to the potency of this approach. However, the identification of 
antigens uniquely expressed or overexpressed by tumor cells and to use those 
antigens as immunogens to trigger antigen-specific T cell responses in patients is still 
a challenge (Gill and Kalos, 2013).  
Intracellular signaling domain is of vital importance for CAR T cells to fulfill their 
antitumor function. The initial CAR of the first generation, which contained a single 
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cytoplasmic signaling domain, provides a proof of concept of the targeting and 
activation of T cells. The CAR of the second and third generations have been 
developed by addition of dual or triple costimulatory signaling domains in order to 
increase their cytotoxicity, cytokines production and proliferation. The most important 
function of multiple signaling receptors is to enhance signaling strength and 
persistence, subsequently increasing their potency (Figure 7) (Han et al., 2013). 
 
Figure 7. The design of successive generations of CARs.  
First-generation CARs contained a single cytoplasmic signaling domain that was derived 
from either CD3ζ. Co-stimulatory signals were lacking in these first-generation CARs, and 
consequently T cell responses against tumor cells were suboptimal. Therefore, second-
generation CARs were developed that contained a co-stimulatory domain, represented in the 
figure by CD28, but could be derived from CD27, CD134, CD137, CD244, inducible T-cell 
co-stimulator (ICOS) or leukocyte C-terminal SRC kinase (LCK). Third-generation receptors 
have an additional signaling domain, represented in the figure by CD137 (Kershaw et al., 
2013).  
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Genetic modification of a T cell with a CAR successfully re-directs the T cell towards 
the desired target. Tumor cell recognition occurs when a CAR on a T cell ligates its 
antigen on the tumor cell. This binding results in CAR clustering with the 
consequence that the immunoreceptor tyrosine-based activation motifs (ITAMs) of 
the signaling moiety become phosphorylated and initiate a downstream signaling 
cascade which finally induces T-cell activation. Activation can lead to direct 
cytotoxicity of tumor target by CAR T cell mediated release of granzyme and perforin. 
Tumor cell killing can also be mediated by activation of other components of the 
immune system through release of cytokines by CD4+ CAR T cells. Long-term 
eradication and prevention against tumor relapse may be provided by long-term 
memory CAR T cells that form after the initial activation (Figure 8) (Chmielewski et 
al., 2013; Davila et al., 2014).  
The synthetic nature of CARs allows for the targeting of a variety of cancers by 
simply substituting various antigen-binding domains, encoded by scFv. The structural 
requirements for efficient targeting of tumor cells by CARs may differ according to the 
tumor antigen recognized and the tumor-antigen recognition domain itself (Baxevanis 
and Papamichail, 2004; Davila et al., 2014). 
Efforts to improve the functions of CARs have typically focused on the intracellular 
signaling domain. However, the affinity of the scFV selected for designing a CAR is 
an additional parameter that could affect T-cell recognition (Hudecek et al., 2013). 
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Figure 8: CAR T cell activation and killing of tumor cells.  
The chimeric antigen receptor (CAR) is expressed on the surface of T cells. Ligation of the 
CAR to the target results in signal transduction through signaling moieties and leads to 
activation of the T cell and killing of the target directly or through engagement of other 
components of the immune system (Davila et al., 2014). 
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8. CAR Clinical Trials 
CAR therapy has already obtained successful results in the clinic. The most 
promising results have been achieved in hematologic malignancies.  Several clinical 
trials have used CAR-transduced T cells targeting the CD19 antigen in patients with 
B cell malignancies (Brentjens et al., 2011; Kalos et al., 2011; Kochenderfer et al., 
2012). Some dramatic responses, together with a remarkable expansion of CAR T 
cells, as well as B cell aplasia, have been observed. In pediatric pre-B cell acute 
lymphocytic leukemia, ACT using CD19-specific CAR T cells could induce the 
complete remission of disease, and CAR T cells were demonstrated to efficiently 
traffic to the bone marrow and cerebral spinal fluid. CAR-modified T cells targeting 
another B cell antigen, CD20, have also shown promise for the treatment of 
lymphoid malignancy. The majority of patients who received anti-CD20 CAR T cells 
maintained stable disease, and two patients achieved partial responses (Till et al., 
2008). Several trials that targeted other tumor antigens like CD171 in neuroblastoma 
(Park et al., 2007), carboxyl anhydrase IX (CAIX) in renal cell carcinoma (Lamers et 
al., 2013) and prostate-specific membrane antigen (PMSA) for prostate cancer 
(Kloss et al., 2013) have been reported.  
In this study, we also hypothesize that T cells can be targeted against the B-Cell 
Maturation Antigen (BCMA) by introducing a transgene that encoded a CAR. 
Therefore, the second aim of this study was to generate a second generation CAR 
against BCMA to treat multiple myeloma (MM) patients.  
  
 
 
 
 
 
 
HYPOTHESIS 
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Adoptive transfer of tumor-reactive cytotoxic T cells is a promising therapeutic 
approach for the treatment of cancer. To develop this strategy, it is necessary to 
obtain tumor cytotoxic T lymphocytes (CTLs) that will be reinfused into the patient 
after expansion in vitro.  
 
Several strategies have been used for obtaining tumor-specific CTLs, such as 
cytokine production assay or soluble pMHC multimers. However, there are some 
limitations that need to be addressed. 1) Selection of CTL based on cytokine 
production assays does not necessarily represent functional cytotoxicity. 2) In order 
to use this approaches the target antigen must be well known, which is not the case 
for most tumor cells. To address these issues, we hypothesized that: 
 
 Hypothesis 1: Tumor-reactive T cells may form strong interactions with 
tumor cells through TCR. This complex (T cell-tumor cell) may occur at 
sufficient frequency and shows enough functional avidity that could be 
isolated by FACS-based cell sorting to pull out naturally occurring tumor-
reactive T cells. 
 
The isolation and use of naturally occurring tumor-reactive T cells have shown 
significant success in treating malignancies. However, there are some difficulties 
associated with the isolation process and feasibility. 1) pMHC multimers can often fail 
to stain antigen specific T cells where the interaction between pMHC and TCR is 
weak. 2) Reproducible results in the clinic with the use of these approaches is often 
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hard to achieve based on the variability between patients. To address these issues 
we thought to generate tumor-specific T cells ex vivo by gene transfer in order to 
infuse them into the patient. Therefore, we also hypothesized that: 
 
 Hypothesis 2: Gene transfer could be exploited to redirect T cells against 
tumor specific antigens expressed on the surface of tumor cells by introducing 
transgenes that encoded chimeric antigen receptors (CAR). 
 
 
   
 
 
 
 
 
OBJECTIVES 
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With these hypotheses the aim of this research project is to develop novel strategies 
of cell therapy in patients with hematologic malignancies and more specifically: 
  
1. To analyze in silico the interaction between the TCR and the pMHC complex 
using Molecular Dynamics, to isolate natural autologous tumor-reactive T 
lymphocytes from acute myeloid leukemia (AML) patients using “Doublet 
Technology” and to confirm their anti-tumor reactivity against blast cells. 
 
2. To generate a second generation CAR against the B-Cell Maturation Antigen 
(BCMA) by genetic modification of T cells to treat multiple myeloma (MM) 
patients and to confirm the anti-tumor reactivity of BCMA CAR T cells against 
myeloma cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
MATERIAL AND METHODS 
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1. Biological Material 
 
1.1.  Healthy Human Samples 
Peripheral blood mononuclear cells (PBMC) from buffy coats of volunteer healthy 
donors were isolated by density gradient centrifugation using Ficoll–Paque solution 
(Amersham Biosciences, Uppsala, Sweden). Buffy coats were kindly donated by the 
Regional Centre for Blood Transfusions at Hospital Universitario Virgen del Rocío, 
Seville (Spain) and the Institutional Review Board of the University of Würzburg 
(Germany). The local ethics committee provided institutional review board approval 
for this study, and informed consent was obtained from all donors in accordance with 
the Declaration of Helsinki. 
 
1.2.  Tumor Human Samples 
1.2.1. Acute myeloid leukemia (AML) 
Blast cells were isolated from bone marrow of AML patients. The percentage of blast 
cells of the sample was higher than 90%. In addition, PBMC from AML patients were 
isolated once they achieved complete remission (CR). Informed consent was 
obtained from all patients in accordance with the Declaration of Helsinki. 
1.2.2. Multiple myeloma (MM) 
Myeloma plasma cells were isolated from bone marrow of MM patients using CD138 
microbead selection (Miltenyi Biotec, Auburn, CA). Informed consent was obtained 
from all patients in accordance with the Declaration of Helsinki. 
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1.3.  Tumor Cell Lines 
1.3.1. Multiple myeloma cell lines 
The MM.1S, OPM-2 and H929 human MM cell lines were purchased from DSMZ 
(Braunschweig, Germany). MM.1S/ffluc and OPM-2/ffluc cells were derived by 
lentiviral transduction with the GFP-firefly luciferase (ffluc)-genes. The MM cell line 
MM.1 was established from the peripheral blood cells of a patient with an IgA 
myeloma. The MM.1 cells are characteristic plasma cells. They are negative for 
CD19 and CD20 found on most normal and malignant B lymphocytes. They have low 
expression of CD10 (common lymphoblastic leukemia antigen), which is found on 
immature B cells, and have low expression of CD45. The MM.1 cells express the 
plasma cell surface marker CD38. The variant MM.1S is sensitive to dexamethasone 
(Greenstein et al., 2003) . OPM cell lines (OPM-1 and OPM-2) were established from 
the peripheral blood of a 56-year-old female myeloma patient at the stage of terminal 
leukemic evolution associated with loss of cytoplasmic immunoglobulin heavy chain. 
The lines synthesized cytoplasmic λ-chain, but had no detectable surface 
immunoglobulins. The lines have very complex chromosomal abnormalities, but the 
patterns of chromosomes differed greatly between the two lines. OPM-2 is 
phenotypically negative for CD10, CD19 and CD20  although it express the plasma 
cell surface marker CD38 (Katagiri et al., 1985). H929 is a highly differentiated 
human plasma cell line. This cell line was established from a malignant effusion in a 
62-year-old female patient with myeloma. The cells have rearranged alpha and 
kappa genes and synthesize and secrete high amounts of IgAk.  They are negative 
for CD10, CD19 and CD20 but possitive for CD38 (Gazdar et al., 1986). All cell lines 
were cultured in tumor cell medium. 
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1.3.2. Other cell lines 
The K562 and K562/BCMA were used as a negative and positive control cell lines. 
K562 was established from pleural effusion of 53 year old female with chronic 
myelogenous leukaemia (CML) in terminal blast crisis. Population highly 
undifferentiated and of the granulocytic series (Andersson et al., 1979). K562/ffluc 
cells were derived by lentiviral transduction with the GFP-firefly luciferase (ffluc)-
genes. Further, K562/BCMA ffluc cells were derived by lentiviral transduction with 
GFP-firefly luciferase (ffluc) and BCMA genes. These cell lines were cultured in 
tumor cell medium. To produce the lentivirus, Lenti-X 293T cell line from Clontech 
was used (Cat.#632180). The 293T cell line is a highly transfectable derivative of 
human embryonic kidney 293 cells, and contains the SV40 T-antigen. To calculate 
the titration of the lentivirus production, Jurkat cell line Clone E6-1 was used (ATCC 
TIB-152). Jurkat is an acute T cell leukemia cell line originally derived from the 
peripheral blood of a 14-year-old boy. TM-LCL cell line from DSMZ (Braunschweig, 
Germany) was used for antigen dependent expansion of CAR T cells. TM-LCL is a 
lymphoblastoid cell line established from normal donor (donor initials: TM) in 1992.  
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2. Non-Biological Material 
 
2.1. Equipment and Consumables  
Equipment, consumables specification                                 Supplier                                                    
 
25, 75 cm2 surface area cell culture flasks Corning, Kaiserslautern, Germany 
96 well half-area plates, Corning® Costar® Corning, Kaiserslautern, Germany 
96 well plate ,white, flat bottom, Corning® Costar®  Corning, Kaiserslautern, Germany 
96, 48, 12, 24 well plates, Corning® Costar® U bottom  Corning, Kaiserslautern, Germany 
AutoMACS ProSeparator Miltenyi, Bergisch Gladbach, Germany 
Biological safety cabinets, Herasafe™ KS Thermo Fisher, Waltham, MA, USA 
Centrifuge tubes, 10, 15, 50 mL Geriener Bio-One, Frickenhausen, Germany 
Centrifuge, Heraeus Megafuge 40R Thermo Fisher, Darmstadt, Germany 
CO2 Incubators, Heracell™ 150i and 240i Thermo Fisher, Darmstadt, Germany 
Electrophoresis power supply, Consort E802 Consort, Turnhout, Belgium 
Facs Aria Fusion Cell Sorter BD Biosciences, Heidelberg, Germany 
Flow cytometer, BD FACSCantoTM II BD Biosciences, Heidelberg, Germany 
Flow cytometery tubes, Röhre 5 mL Sarstedt, Nümbrecht, Germany 
Gel electrophoresis system, Owl™ Minigel Thermo Fisher, Darmstadt, Germany 
Gel imaging system, ChemiDocTM MP Bio-Rad, Munich, Germany 
Heat block, neoBlock1  neoLab, Heidelberg, Germany 
Ice maker Scotsman, Vernon Hills, IL, USA 
Incubator Memmert, Schwabach, Germany 
Leucosep tubes Geriener Bio-One, Frickenhausen, Germany 
MACS separation columns, 25 LS Miltenyi, Bergisch Gladbach, Germany 
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Microcentrifuge, Fresco 17 Thermo Fisher, Darmstadt, Germany 
Microscope, Primo Vert  ZEISS; Jena, Germany 
Mini-PROTEAN Tetra Cell Bio-Rad, Munich, Germany 
Multimode multiplate reader ,Infinite 200 PRO TECAN- Männedorf, Switzerland 
NanoDrop 2000 Thermo Fisher, Darmstadt, Germany 
Refrigerator, -4 and -20  °C Liebherr, Bulle, Switzerland 
Shaker Incubator  INFORS HT, Basel, Switzerland 
Trans-Blot Turbo Transfer Pack Bio-Rad, Munich, Germany 
Ultracentrifuge, Sorvall WX80 Thermo Fisher, Darmstadt, Germany 
Ultra-low temperature freezer, -80  °C FORMA 900  Thermo Fisher, Darmstadt, Germany 
UV transilluminator  neoLab, Heidelberg, Germany 
Vivaspin 6 MWCO 50.000 GE Healhcare, Uppsala, Sweden 
Water bath Memmert, Schwabach, Germany 
 
 
 
2.2. Software 
Software Application Company 
FlowJo X 10.0.7 FACS analysis Tree Star Inc. Ashland, OR, USA 
GraphPad Prism 6 statistical analysis La Jolla, CA, USA 
IBM SPSS statistical analysis New Orchard Road Armonk, NY 
Image Lab™ Software T7EI analysis Bio-Rad, Munich, Germany 
InfinicytTM FACS analysis Cytognos S.L., Salamanca, Spain 
ModFit Suppression analysis Topsham ME, US 
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2.3. Chemicals and Reagents  
2.3.1. Molecular biology  
 
Name                                
 
 
Manufacturer                                                     
1 Kb DNA Ladder NEB, Frankfurt am Main, Germany 
100 bp DNA Ladder NEB, Frankfurt am Main, Germany 
Dual Xtra Standards Bio-Rad, Munich, Germany 
Ethanol absolute for molecular biology AppliChem, Darmstadt, Germany 
GelRedTM Nucleic Acid Gel Stain  Biotium, Fermont, CA, USA 
Isopropyl alcohol  Sigma-Aldrich, Steinheim, Germany 
LB Agar plates with 100 µg/mL Carbenicillin TEKnova, Hollister, CA, USA 
LB broth 1x  Thermo Fisher, Darmstadt, Germany 
LDS Sample Buffer, Non-Reducing (4x) Thermo Fisher, Darmstadt, Germany 
Methanol Sigma-Aldrich, Steinheim, Germany 
NheI NEB, Frankfurt am Main, Germany 
NuPAGE® LDS Sample Buffer (4x) Invitrogen, Karlsruhe, Germany 
NuPAGE® Sample Reducing Agent (10x) Invitrogen, Karlsruhe, Germany 
Phosphatase Inhibitor Cocktail Sigma-Aldrich, Steinheim, Germany 
Precision Plus Protein™ Kaleidoscope Bio-Rad, Munich, Germany  
Protease Inhibitor Cocktail Sigma-Aldrich, Steinheim, Germany  
Tris-EDTA Buffer Solution (TE, pH 8.0) Sigma-Aldrich, Steinheim, Germany 
Water, molecular biology grade AppliChem, Darmstadt, Germany 
Western ECL substrate Bio-Rad, Munich, Germany 
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2.3.2.  Cell culture and immunology  
 
Name                                
 
    Manufacturer                                                     
2-Mercaptoethanol Life Technologies, Darmstadt, Germany 
Anti-biotin MicroBeads Miltenyi, Bergisch Gladbach, Germany 
Anti-PE MicroBeads Miltenyi, Bergisch Gladbach, Germany 
Cell trace CFSE  Life Technologies, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany 
D-Luciferin firefly, Potassium Salt  Biosynth, Staad, Switzerland  
Dulbecco's Phosphate-Buffered Saline (DPBS) Life Technologies, Darmstadt, Germany 
Dynabeads® Human T-Activator CD3/CD28 Life Technologies, Darmstadt, Germany 
Ethylenediaminetetraacetic acid (EDTA ) 0.5 M Life Technologies, Darmstadt, Germany 
Fetal calf serum (FCS) Life Technologies, Darmstadt, Germany 
GlutaMax-I 100X Life Technologies, Darmstadt, Germany 
HEPES 1M Life Technologies, Darmstadt, Germany 
Human Serum  Bayerisches Rotes Kreuz 
Ionomycine Sigma-Aldrich, Steinheim, Germany 
PBS, pH 7.4, contains TWEEN® 20 (dry 
powder) 
Sigma-Aldrich, Steinheim, Germany 
PE Streptavidin 0.2 mg/mL BioLegend, Fell, Germany 
Penicillin/Streptomycinn 10,000 U/mL Life Technologies, Darmstadt, Germany 
Phorbol 12-myristate 13-acetate (PMA)  Sigma-Aldrich, Steinheim, Germany 
Polybrene (Millipore, 10 mg/mL) Merck, Darmstadt, Germany 
Recombinant human IL-2 (PROLEUKIN ® S) Novartis, Basel, Switzerland  
RPMI 1640 Medium, GlutaMAX™ Supplement Life Technologies, Darmstadt, Germany 
Trypan blue  Life Technologies, Darmstadt, Germany 
Strategies to Obtain Tumor-reactive Cells                              
 
 
 
 
74 
2.4. Media and Buffers  
T cell medium (TCM)             
1640 RPMI, with 25 mM HEPES and Glutamax  500 mL 
Human Serum (heat inactivated at 56 °C for 30 min) 10% 
Penicillin/Streptomycinn 10,000 U/mL 100 U/mL 
GlutaMax-I 100X 1% 
2-Mercaptoethanol 50 mM  0.1% 
Mix all components and filter sterilize (0.22 µm)  
 
Tumor cells medium   
1640 RPMI, with 25 mM HEPES and Glutamax 500 mL 
FCS  10% 
Penicillin/Streptomycinn 10,000 U/mL 100 U/mL 
GlutaMax-I 100X 1% 
Mix all components and filter sterilize (0.22 µm)  
 
MACS buffer  
DPBS 500 mL 
EDTA 0.5 M 0.4% 
FSC 0.5% 
Mix all components and filter sterilize (0.22 µm)  
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FACS buffer 
DPBS 500 mL 
EDTA 0.5 M 0.4% 
FSC 0.5% 
Sodium azide (NaN3) 0.1% 
 
PBS/EDTA  
DPBS     500 mL 
EDTA 0.5 M        0.4% 
FSC   0.5% 
 
RIPA BUFFER 
TRIS-HCL                                                                                                      50 mM 
NaCl                                                                                                      150 mM 
ddH2O                                                                                                            75 mL 
 
TBS 10x BUFFER 
TRIS                                                                                                               24.2 g 
NaCl                                                                                                         87.7 g 
ddH2O                                                                                                       700 mL 
 
TBS-T 1x BUFFER 
TBS 10x                                                                                                         50 mL 
Tween 20                                                                                             500 µL 
ddH2O                                                                                                       450 mL 
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2.5. Commercial Kits 
Name Manufacturer 
CalPhos Mammalian Transfection Kit Clontech, Taraka 
CD3 MicroBeads, human Miltenyi Biotec 
CD4+ T Cell Isolation Kit, human Miltenyi Biotec 
CD8+ T Cell Isolation Kit, human Miltenyi Biotec 
DC Protein Assay Kit II Bio-Rad 
ELISA Max™ Set Deluxe (IL-2 and IFNγ kits) BioLegend 
Endofree Plasmid MAXI Kit QIAGEN 
Human BCMA/TNFRSF17 DuoSet ELISA R&D Systems 
MINI PROTEAN TGXTM Gels Bio-Rad 
PE Annexin V Apoptosis Detection Kit with 7-AAD BD Biosciences 
PKH67GL-1KT Kit Sigma-Aldrich 
Trans-Blot® Turbo™ RTA Mini LF PVDF Transfer Kit Bio-Rad 
 
2.6. Antibodies 
2.6.1. Flow cytometry 
Ligand  Clone/Poly Conjugation Isotype Manufacturer 
BCMA 19F2 APC Mouse IgG2a, κ Biolegend 
CCR7 150503 PE Mouse IgG2a BD Biosciences 
CD127 A019D5 PE Mouse IgG1, k Biolegend 
CD138 DL-101 PE Mouse IgG1, κ Biolegend 
CD25 2A3 PE Mouse IgG1, k BD Biosciences 
CD25 BC96 Pacific Blue Mouse IgG1, k Biolegend 
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CD3 BW264/56 APC Mouse IgG2a, k Miltenyi 
CD3 SK7 PerCP Mouse IgG1, k BD Biosciences 
CD3 17A2 APC/Cy7 Mouse IgG1, κ Biolegend 
CD38 HIT2 Brilliant Violet 421 Mouse IgG1, κ Biolegend 
CD4 SK3 PerCP Mouse IgG1, k BD Biosciences 
CD4 M-T466 VioBlue Mouse IgG1, k Miltenyi 
CD4 RPA-T4 APC/Cy7 Mouse IgG1, k BD Biosciences 
CD45 HI30 Pacific Blue Mouse IgG1, k BD Biosciences 
CD45 HI30 PE/Cy7 Mouse IgG1, k Biolegend 
CD45 HI30 Pacific Orange Mouse IgG1, k BD Biosciences 
CD69 FN50 FITC Mouse IgG1, k Biolegend 
CD8 BW135/80 VioBlue Mouse IgG2a, k Miltenyi 
CD8 SK1 APC Mouse IgG1, k BD Biosciences 
EGFR (Cetuximab) C225 Biotin Human IgG1, k ImClone LLC 
EGFR (Cetuximab) C225 AlexaFluor 647 Human IgG1, k ImClone LLC 
FoxP3 259D/C7 APC Mouse IgG1, k BD Biosciences 
TCR γ/δ B1 PE/Cy7 Mouse IgG1, k Biolegend 
 
2.6.2. Western blot 
Name   Antibody Dilution Manufacturer 
BCMA polyclonal goat   Primary 1:10000   R&D Systems 
Goat-IgG HRP  Secondary 1:1000   R&D Systems 
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3. Molecular Dynamics 
The published structures solved by XRD served as a starting point for this study. The 
HLA-A2/TAX/TCR-A6 system was chosen because it has been extensively studied 
experimentally, as the three peptide mutants (P6A, V7R, Y8A). The initial coordinates 
of the complexes were downloaded from Protein Data Bank (Berman et al., 2002) 
access codes: 1ao7 (TAX wild-type ternary complex), 1qse (V7R-TAX), 1qrn (P6A-
TAX), 1qsf (Y8A-TAX). TAX (LLFGYPVYV) differs from the other peptides by single 
amino acid substitutions causing very different behaviors in T cells (Ding et al., 1999).  
MD trajectories were calculated with AMBER version 9. Standard protocols were 
used to carry out computational assays (Aroca et al., 2011). Simulations were carried 
out under periodic boundary conditions in an orthorhombic cell solvated with TIP3P 
explicit water (Jorgensen et al., 1983). A first energy minimization was performed on 
sidechains. Then, solvent was subjected to energy minimization followed by 300 ps 
NPT-MD computations. Temperature was regulated with Berendsen’s algorithm 
(Berendsen et al., 1984). Then, for each protein, the whole system was energy 
minimized and submitted to 1 ns NVT-MD at 298 K, using 2.0 fs integration time 
steps for temperature equilibration. Production runs were computing under the 
microcanonical ensemble. The trajectories were analyzed with the PTRAJ module of 
the AMBER package, MatLab 7.11 (MathWorks) and Origin8.5 (OriginLab). 
Conformational entropies were estimated by using the standard approaches 
implemented in the PTRAJ module of AMBER. DelPhi v.5.1 was used to analyze 
protein electrostatics by solving the Poisson-Boltzmann equation by a finite difference 
method. Protein dielectric constant value was set to 4 and grid size to 0.5 Å. 
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4. Doublet Cell Culture and Functional Tests 
 
4.1. PBMC Purification  
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donors 
peripheral blood (Donor) or AML patient peripheral blood in complete remission 
status (CR) by density centrifugation over Ficoll-Hypaque. Blood was mixed with 
room temperature DPBS at 8:1 ratio. Density centrifugation was performed for 30 min 
at 400xg with acceleration and deceleration settings of 9 and 2, respectively. The 
mononuclear cell layer, found between the Ficoll and the serum layer, was extracted 
and washed twice with TCM to eliminate traces of Ficoll. Finally, the PBMC were 
cultivated in a 48 well plate a final concentration of 1x106 cells/ml. 
 
4.2. CD3 Depletion and Irradiation 
PBMC or blast cells were isolated from healthy donors peripheral blood (target) or 
AML patient bone marrow, respectively. Samples were mixed with room temperature 
DPBS at 8:1 ratio. Density centrifugation was performed for 30 min at 400xg with 
acceleration and deceleration settings of 9 and 2, respectively. The mononuclear cell 
layer was extracted and washed twice with TCM. CD3+ cells (T cells) were depleted 
twice using CD3 MicroBeads, human (Miltenyi Biotec) following the manufacturer's 
instructions. Then, the CD3 depleted-PBMC (CD3-PBMC) were irradiated at 25Gy. 
After irradiation, CD3-PBMC were stained with a nonspecific labeling PHK-67 which 
is FITC channel positive (CD3-PKH+PBMC).   
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PKH-67 Protocol 
1-Determine number of cells 
2- Add 500 µl Diluent C per 5x106 cells (Solution 1) 
3- Prepare 2 µl PKH-67 per 500 µl of Diluent C (Solution 2) 
4- Mix Solution 1 and 2 in a ratio 1:1 
5- Incubate on ice for 3 min and 45 sec in the dark and mixing 
6- Add 2ml of human serum per ml of mixed solution to stop the staining 
7- Incubate on ice for 1 min and wash twice with TCM 
 
 
4.3. Primary Co-Culture 
For setting up the technique, we co-cultured PBMC from donor 1 (donor) against 
irradiated CD3-PKH+PBMC from donor 2 (target) at 3:1 ratio in a 48 well plate with 
TCM (Figure 9A). Regarding clinical application, we co-cultured patient´s blast cells 
against PBMC from the same patient in CR status (Figure 9B). The co-culture was 
incubated at 37°C without shaking. The cell cultures were analyzed at different time 
points (2, 15, 24, 48 hours) by flow cytometry to study the percentage of doublet T 
cells (T cell bound to a tumor cell through TCR).  
The following panel was used: PKH-FITC/CD3-APC/CD45-PB 
 
 
Figure 9. Co-culture in setting up condition (A) and clinical setting (B). 
 
 
A B 
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4.4. FACS-Based Cell Sorting 
After 15 hours of co-culture, 2/3rds of the volume was removed from each well 
without touching the cells on the bottom of the well (the volume in the well was 
reduced e.g. 48-well from 1 mL to 333 uL). The following antibodies were added 
directly to the well: CD25-PE/CD3-APC/CD45-PB. The antibodies were incubated at 
room temperature in dark for 30 min. Cells were harvested and washed with cold 
DPBS for 10 min at 220xg. After the second wash step, the supernatant was 
removed and the cells were resuspended in DPBS. FACS Aria Fusion Cell Sorter 
was used to sorter the different populations. The sorting strategy was: First, the 
viable region FSC/SSC and positive region for CD45 was selected. Then, double 
positive cells (CD3+PKH+) and non-doublets cells (CD3+PKH-) were gated. Finally, 
within the non-doublets cells (CD3+PKH-), two different populations were sorted 
using the antibody CD25 (Figure 10). The nozzle size used to sorter the doublets 
cells was 85 µm. The sorted populations were analyzed in order to verify the purity of 
the sorting procedure. 
Figure 10. Sorting strategy 
 
Once the cells were sorted, two washing steps were developed. The different 
populations were resting overnight (20 hours) in a 96 well plate with TCM. After the 
resting period, half medium change was performed. 
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4.5. Immunophenotype 
Doublet/non-doublet T cells were analyzed by flow cytometry and groups were 
compared regarding CD4+/CD8+ proportions, naïve/effector/central memory/effector 
memory proportions and regulatory markers. Flow analyses were performed on a BD 
FACSCanto II and data analyzed using Infinicyt software (Cytognos). 
 
4.6. Secondary Co-Cultures 
 
4.6.1. Cytotoxicity assay 
Secondary co-cultures were performed in a 96 well plate U-bottom at 37°C. Target 
CD3-PBMC (depleted of T cells) were thawed in TCM. After the second wash step, 
the supernatant was removed and the cells were stained with PKH-67 (CD3-
PKH+PBMC). Co-cultures of sorted doublet/non-doublet T cells from donor with 
target CD3-PKH+PBMC (used in primary co-culture) were maintained for 7 hours. In 
the clinical application context, tumor cells from the same patient (used in primary co-
culture) were stained with PKH-67 or a tumor marker. Co-cultures of patient’s doublet 
/non-doublet T cells with tumor cells were also maintained for 7 hours. The cytotoxic 
activity of doublet population vs non-doublet population was analyzed by flow 
cytometry using Annexin V / 7AAD staining. The viable cells were Annexin V negative 
and 7AAD negative. 
 
4.6.2. Suppression assay 
To test regulatory functions, co-cultures of non-doublet T cells with activated 
conventional T cells were performed. PBMC from healthy donors were isolated by 
density gradient centrifugation. Conventional T cells (CD3+ cells) were purified by 
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positive isolation using Miltenyi MACS MicroBeads and magnetic cell separation 
protocol according to manufacturer’s instruction. The conventional T cells were 
stained with PKH-67 and stimulated with plate bound anti-CD3 (10 μg/mL) and 
soluble anti-CD28 (1 μg/mL) mAbs. An increasing proportion of conventional T cells 
was used for studying the inhibition function of non-doublet T cells.  After 4 days, 
cells were collected, stained with CD3-APC, 7AAD, CD25-PB and CD45-PO mAbs 
and analyzed by flow cytometry. ModFit software was used to calculate the 
percentage of resting and proliferating cells. 
 
4.6.3. Activation assay 
The sorted doublet/non-doublet T cells from donor were co-cultured with target CD3-
PKH+PBMC. Moreover, the cells were activated with anti-CD3/CD28 beads in cell to 
bead ratio of 1:3 as a control and CD69 activation marker was studied by flow 
cytometry at 24 h after the secondary co-culture.  
Populations Secondary Co-cultures Analyses 
 
SETTING  
 
CD3+PKH+ 
(doublet T cells) 
 
 
 
Target CD3-PKH+PBMC 
 
 
 
Immunophenotype 
Cytotoxicity 
Suppression  
Activation 
CD3+ PKH- 
(non-doublet T cells) 
Target CD3-PKH+PBMC 
 
 
 
CLINICAL APPLICATION 
 
pCD3+PKH+ 
(patient doublet T cells) 
 
 
 
Tumor cell patient 
 
 
 
Immunophenotype 
Cytotoxicity 
pCD3+ PKH- 
(patient non-doublet T cells) 
Tumor cell patient 
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5. CAR Manufacturing and Functional Tests 
 
5.1. Preparation of BCMA CAR-Encoding Plasmids 
DNA sequences encoding the BCMA CARs were designed. The sequence of each 
CAR followed this pattern from the 5′ end to the 3′ end: the GM-CSF signal sequence 
(22 amino acid; Uniprot Database: P15509), single chain variable fragments (scFv), 
IgG4 hinge (short: 12 amino acid; long: 229 amino acid; Uniprot Database: P01861) 
and transmembrane regions of the human CD28 molecule (27 amino acid; Uniprot 
Database: P10747), the cytoplasmic portion of the 4-1BB costimulatory molecule (42 
amino acid; Uniprot Database: Q07011), and the cytoplasmic portion of the CD3ζ 
molecule (112 amino acid, Uniprot Database: P20963). DNA encoding the CARs was 
codon optimized and synthesized by GeneArt AG with appropriate restriction sites. 
Products of GeneArt were transformed in competent cells of Escherichia coli strain 
Top10 (Invitrogen) and plated onto LB agar plates containing 100 μg ampicillin/ml. 
Transformants were transferred to a mattress with LB Broth 1X medium containing 
100 μg ampicillin/ml  and incubated overnight at 37ºC with vigorous shaking (230 
rpm). BCMA CAR-encoding plasmids DNA were extracted using EndoFree Plasmid 
Maxi Kit (QUIAGEN). 
 
5.2. Preparation of Viral Vectors 
Lentiviral vectors were produced in 293T-HEK cells (Lenti-X). To produce BCMA 
CARs lentiviral vectors, 15 µg of BCMA CAR-encoding plasmids and 10 µg, 1 µg and 
2 µg of three helper plasmids, PCHGP-2, PCMV-Rev2 and PCMV-G, were used per 
10 cm2 petri dish, respectively. Lenti-X cells were cultured at 80% cell confluency in 
10 cm2 petri dishes, with three plates being used for one batch of lentivirus and 
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incubated for six hours to allow the cells to settle. Transfection with the lentiviral and 
helper plasmids was performed using a calcium phosphate-based method 
(Clontech). The plasmids at the appropriate ratios and amounts were diluted in 2 M 
CaCl2 solution and the final volume set to 500 µL per petri dish with dH2O (1500 µL 
for 3 plates). The plasmid mixture was drop wised added to equal volume of 2x 
HEPES-buffered saline (HBS). The mixture (3 mL) was incubated for 20 min at room 
temperature, equal amount of DMEM/10%FCS were added to the mixture and 2 mL 
of the final DNA suspension was added to each plate in a slow drop-wise manner 
and the plates were gently twirled to distribute the DNA mixture evenly. Plates were 
incubated at 37 °C overnight. Viral supernatant from 3 plates were collected into one 
50 mL centrifuge tube 72 hours after transfection, centrifuged at 2160 x g for 15 min 
at 8 ºC to remove any cell debris, passed through a 0.45 µm vacuum filter unit and 
was added to one centrifuge tube. The tube was under laid with 4 mL of 20% 
sucrose. The sample was centrifuged at 138510 x g for 2 hours at 4 ºC by an 
ultracentrifuge. The viral pallet was covered with 200 µL of DPBS and after at least 3 
hours incubation at 4 °C was resuspended and aliquoted in 20 µL fractions. Viral 
vectors were stored at -80 °C for future use. 
 
5.3. Titration of Lentivirus 
In order to determine the viral titration, Jurkat cells were plated in a 48-well plate at a 
cell density of 1x106 cells/mL in 250 μL of tumor cell lines culture medium with 5 
μg/mL polybrene that facilitates viral entry into cells. Serial dilutions of lentivirus (0, 
0.0626, 0.125, 0.25, 0.5, 1, 2.5 or 5 μL) were added to consecutive wells and 
incubated for 4 hours at 37 °C. Following incubation, the medium was topped up to 1 
mL and the cells cultured for another 48 hours. CAR expression was analyzed by 
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flow cytometry using the EGFRt transduction marker encoded within the lentiviral 
vector. The lentivirus titer in transforming units (TU)/mL was calculated using the 
following equation based on the percentage of EGFRt positive cells for CAR 
constructs: 
Virus titer (
TU
mL
)= 
Cell count at day of transduction + 
% EGFRt+ /alive cells
100
Volume of virus added (mL)
 
  
 
5.4. Isolation of Human T Cell Subsets 
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donor 
peripheral blood by density centrifugation over Ficoll-Hypaque. Blood was mixed with 
room temperature DPBS at maximum final volume of 35 mL and were carefully 
added to a 50 mL leucosep tube that was previously equilibrated with 15 mL of room 
temperature separation medium. Density centrifugation was performed for 15 min, at 
350 x g, at 22 °C, with acceleration and deceleration settings of 9 and 2, respectively. 
The PBMC accumulate beneath the plasma and above of the leucospe tube filter. 
These cells were washed twice with cold (4 °C) PBS/EDTA buffer, and centrifuged at 
4 °C at 220 x g for 15 min. These cells were then directly used for MACS separation. 
CD8 and CD4 bulk were purified by negative isolation using Miltenyi MACS 
MicroBeads and magnetic cell separation protocol according to manufacturer’s 
instruction. For magnetic separation, LS columns were used for up to 150x106 cells. 
Isolated cells were activated by anti-CD3/CD28 Dynabeads in cell to bead ratio of 1:1 
for further experimental procedures.  
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5.5. Lentiviral Transduction of T Cells 
Prior to lentiviral transduction, T cells were cultured in a 48 well pate at a density of 
0.5 x106 T cells per well in TCM (T cell culture medium) with 50 U/mL rh IL-2 and 
were activated with anti-CD3/CD28 Dynabeads. The following day, 2/3 of medium 
was removed; CAR-encoding lentivirus at a multiplicity of infection (MOI) of 5, and 
polybrene at a final concentration of 5 μg/mL were added to T cells, and inoculation 
performed by centrifugation at 800 x g for 45 min at 32 °C. Following centrifugation, 
the T cells were immediately transferred to 37 °C, rested for 4 hours, and then 1 mL 
of fresh, warm TCM and 50 U/mL rh IL-2 were added to each well. During 
subsequent days, a half-medium change with pre-warmed TCM was performed and 
rh IL-2 supplemented to a final concentration of 50 U/mL every second day. The anti-
CD3/CD28 Dynabeads were removed using a hand-held magnet on day 6 post-
stimulation and the T cells were transferred to larger plates or tissue culture flasks 
(12-well plate, then T25 flask) as appropriated to propagate.  
 
5.6. Enrichment of CAR+ T Cells 
Prior to functional testing, EGFRt-positive T cells transduced with BCMA CARs viral 
vectors were enriched using biotin-conjugated anti-EGFR mAb and anti-biotin 
MicroBeads (Miltenyi), and were expanded in an antigen dependent manner with 
irradiated TM-LCL feeder cells for 7 days. 
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5.7. Antigen Dependent Expansion  
Following enrichment, and before functional assays, EGFRt+ CD8+ and CD4+ T-cell 
subsets were expanded by irradiated TM-LCL (80 Gy) cells at a T cell: LCL ratio of 
1:7. Next day, cultures were supplemented with 50 U/mL of rh IL-2 and cells were fed 
with fresh TCM and 50 U/mL rh IL-2 every second day. The phenotype of the 
expanded T cell lines was analyzed on day 7 of expansion. 
 
5.8.  Immunological and Functional Tests 
 
5.8.1. Immunophenotype 
T cells were washed by centrifugation at 200 x g for 4 min with FACS buffer and 
stained with the following conjugated mAbs: CD4, CD8, EGFRt in FACS buffer and 
incubated for 25 min at 4 °C, washed as above; cells were resuspended in FACS 
buffer before flow cytometry measurement. Viability staining solution 7-AAD was 
used for exclusion of dead cell. CAR+ (EGFRt+) T cells were detected by staining 
with biotin-conjugated anti-EGFR antibody (ImClone Systems Inc.) and streptavidin-
PE or by staining with anti-EGFR antibody conjugated to AlexaFluor 647. Flow 
analyses were performed on a BD FACSCanto II and data analyzed using FlowJo 
software (Treestar). 
 
5.8.2. Cytotoxicity assay 
Target cells expressing firefly luciferase were incubated in triplicate at 5x103 
cells/well with effector T cells at various effector to target (E: T) ratios in 96-well white 
flat bottom plate in a final volume of 150 µL. After 4-hour incubation, luciferin 
substrate was added to the final concentration of 0.3 mg/mL to the co-culture and the 
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decrease in luminescence signal in wells that contained target cells and T cells was 
measured using a luminometer (Tecan) and compared to target cells alone. Specific 
lysis was calculated using the standard formula (Brown et al., 2005) .  
 
5.8.3. Cytokine secretion assay and ELISA  
5x104 T cells were plated in triplicate wells with target cells at a ratio of 2:1 (MM1.S), 
or 4:1 (OPM-2, H929, K562/BCMA and K562), and IFN-γ and IL-2 production were 
measured in supernatant removed after a 24-hour incubation by ELISA kits 
(BioLegend) based on manufacturer’s protocol. 
 
5.8.4. CFSE proliferation assay  
For analysis of proliferation, 5x104 T cells were labeled with 0.2 μM 
carboxyfluorescein succinimidyl ester (CFSE, Thermo Fisher), washed and plated in 
triplicate wells with target cells at a ratio of 2:1 (MM1.S), or 4:1 (OPM-2, H929, 
K562/BCMA and K562) in medium without exogenous cytokines. After 72-hour 
incubation, cells were labeled with anti-CD8/CD4 mAbs and 7-AAD to exclude dead 
cells from analysis. Samples were analyzed by flow cytometry and division of living T 
cells was assessed by CFSE dilution. The proliferation index was calculated using 
FlowJo software. 
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5.9.  Functional Tests in The Presence of Soluble BCMA 
 
5.9.1. Cytotoxicity assay 
MM1.S and K562/BCMA cells expressing firefly luciferase were incubated in triplicate 
at 5x103 cells/well with effector T cells at various effector to target (E: T) ratios in 96-
well white flat bottom plate in the presence of 150 ng/ml of soluble BCMA protein. 
After 4-hour incubation, luciferin substrate was added to the final concentration of 0.3 
mg/mL to the co-culture and the decrease in luminescence signal in wells that 
contained target cells and T cells was measured using a luminometer (Tecan) and 
compared to target cells alone. Specific lysis was calculated using the standard 
formula (Brown et al., 2005) .  
 
5.9.2. Activation assay  
1x105 T cells were plated in triplicate wells with soluble BCMA at different 
concentrations: 0, 37.5, 75 or 150 ng/ml and incubated for 24 hours. Activated T cells 
(CD25+CD69+ cells) were analyzed by flow cytometry using FlowJo software. 
Moreover, IFN-γ production was measured in supernatant removed after 24-hour 
incubation by ELISA kits (BioLegend) based on manufacturer’s protocol. 
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6. Western Blotting 
To analyze the soluble form of BCMA (sBCMA) Western Blott assay was developed. 
For that, 15-20 ml of supernatant of K562/BCMA and K562 cell lines was used. To 
concentrate the sBCMA, the supernatant was added into a Vivaspin 20 tube and 
centrifuge at 5000 x g for 120 min at 20 °C. Also, the membrane form of BCMA 
(mBCMA) was studied. For that, K562/BCMA and K562 cells were harvested by 
centrifugation at 220 x g for 10 min at 20 °C.  The cells were washed twice with cold 
DPBS and resuspended in 100 µl of RIPA buffer (supplemented with Protease 
Inhibitor Cocktail and Phosphatase Inhibitor Cocktail) and incubated on ice for 5 min. 
The samples were cracked in liquid nitrogen. After centrifugation at 8000 x g for 10 
min at 4°C, the supernatant was transferred into a new tube. The protein 
concentration was determined using DC Kit (Bio-Rad). For non-reducing condition, 
LDS sample buffer Non-Reducing (4x) was used. For reducing condition, LDS 
sample buffer (4x) and Sample reducing agent (10x) were used. SDS-PAGE gels 
were prepared following standard protocols. The percentage of polyacrylamide was 
4-20%. Electrophoresis was conducted at a constant voltage of 50 during the first 30 
min and then increased to 100 V. Gels were transferred to PVDF membranes by 
semi-dry transfer. The transfer  was performed at constant amperage of 50 mA for 90 
min. Membranes were blocked in TBS-T buffer + 5% BSA and incubated with primary 
antibody overnight on shaker at 4°C, followed by incubation with the appropriate 
horseradish peroxidase (HRP) conjugated secondary antibody for 1 h at room 
temperature. Finally, membranes were washed twice with TBS-T buffer and once 
with deionized water. Detection was performed with Western ECL substrate following 
the manufacturer’s protocol. Bands were visualized by using ImageJ software.  
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7. Preclinical in Vivo Experiments 
 
7.1. Multiple Myeloma Xenograft Model (NSG/MM1.S-ffLuc) 
The University of Würzburg Institutional Animal Care and Use Committee approved 
all mouse experiments. Six- to eight-week old female NSG mice were obtained from 
Charles River and inoculated by tail vein injection with 2x106 firefly luciferase 
expressing MM1.S tumor cells. On day 14, development of systemic myeloma was 
documented by bioluminescence imaging. Bioluminescence imaging was done on an 
IVIS Lumina (Perkin Elmer, Waltham, MA) following intraperitoneal injection of D-
luciferin (0,3mg/g body weight), and data analyzed using Living Image Software 
(Perkin Elmer). 
 
7.2. Adoptive Transfer of T Cells and Analysis of Antitumor Efficacy  
On day 14, groups of n=4 mice received intravenous injections of 5x106 BCMA CAR-
modified or unmodified control (mock) T cells containing equal proportions of CD8+ 
and CD4+ T cells. Bioluminescence imaging was performed weekly to determine 
tumor burden and distribution in mice. Finally, survival of mice was analyzed by 
Kaplan-Meier analysis. 
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8. Statistical Analysis 
All data are presented as mean ± standard deviation/range of either absolute values 
or percentages. Statistical analyses were performed using IBM SPSS Statistics or 
GraphPad Prism softwares. Statistical significance was assessed by paired Student’s 
t-test or Mann-Whitney test. In all the tests, p values were p < 0.05 (*), p < 0.01 (**) 
and p < 0.001 (***). 
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PART I 
 
“DOUBLET TECHNOLOGY” TO OBTAIN  
TUMOR-REACTIVE T CELLS 
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The first objective of this study was to analyze the interaction between the TCR and 
the pMHC complex and to develop a new strategy for obtaining natural tumor-
reactive T cells from the pool of patient´s lymphocytes to treat hematologic 
malignancies. In particular, we developed the so called “Doublet Technology” to 
identify and isolate specific cytotoxic T lymphocytes (CTLs) in patients diagnosed 
with acute myeloid leukemia (AML) with the aim of tailoring therapy for each patient.  
Therefore, we first performed molecular dynamics simulations to study the strength of 
the pMHC-TCR interaction using a range of peptides with different immune reactivity. 
To develop our “Doublet Technology” we used the cells of healthy donors due to the 
easy availability and feasibility. Once the co-culture conditions and sorting strategy 
were settled up, the “Doublet Technology” was confirmed with AML patient samples. 
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1. Reactivity of pMHC Complexes Correlates with The Strength of 
pMHC-TCR Interaction 
 
1.1. Model system 
The kinetic model states that T cell signaling is highly dependent on the dissociation 
rate of peptide-major histocompatibility (pMHC) from T cell receptor (TCR). Thus, 
pMHC-TCR complexes with slow dissociation rates send positive signals to T cell 
with the consequence that the T cell become activated (McKeithan, 1995; Rabinowitz 
et al., 1996). Therefore, we performed molecular dynamics (MD) trajectories to study 
the interaction between pMHC and TCR at the molecular level.  
The model system chosen was the well-defined human A6 TCR which is specific for 
an antigen of the human T cell lymphotropic virus HTLV-1, which is responsible to 
cause adult T-cell leukemia/lymphoma. The A6 TCR binds to the TAX oligopeptide 
(LLFGYPVYV) bound to the human class I MHC molecule HLA-A2 (Garboczi et al., 
1996). The TAX peptide is a strong agonist that induces T-cell activation at very low 
concentrations. Single mutations on TAX inhibit T-cell function instead of triggering it. 
The interactions of three peptide variants (P6A, V7R and Y8A) of TAX bound to HLA-
A2 with the A6 T cell receptor have been extensively studied using T cell assays, 
kinetic and thermodynamic measurements, and X-ray diffraction (XRD). The V7R 
mutant weakly reacts and elicits the distinct cell responses at concentrations two 
orders of magnitude higher than TAX. The P6A and V8A species can be considered 
unreactive, as they barely induce any response even at concentrations which are 
several orders of magnitude higher than those at which the response to wild-type 
species saturates (Ding et al., 1998; Ding et al., 1999).  
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To summarize:  
 TAX-HLA-TCR: wild-type reactive complex 
 V7R-HLA-TCR: mutant weakly reactive complex 
 P6A-HLA-TCR and Y8A-HLA-TCR: mutant non-reactive complexes 
 
1.2. Stability of computational simulations 
Ten MD trajectories were set up to simulate the behavior of isolated components of 
the different peptide-HLA-TCR complexes. We first demonstrated that all the 
complexes show a high structural similarity (Figure 11) but a different functional 
behavior (Ding et al., 1999).  
 
Figure 11. Overlay of the X-ray diffraction models for the WT and mutant TAX-HLA-
TCR complexes. All the panels show an overlay of the Cα atoms of the TAX-HLA-TCR 
complex (pdb: 1ao7) with those corresponding to V7R (pdb: 1qse) P6A (1qrn) and Y8A (pdb: 
1qsf). A) Overlay of the full complex. TCR molecules are shown in black lines. Black ball-
and-sticks represent the antigenic peptide. The HLA domain containing the peptide is 
depicted in dark grey lines while the remaining structure is shown in light grey. B) Detail of 
the ternary complex interface for the structure overlay in (A). C) Apical view of TCR and the 
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antigenic peptide in the above overlay of the four structures. As in (A), TCR atoms are 
represented by lines, but those from residues closer than 6 Å from HLA are highlighted by 
stick representation. D) Apical view of HLA and the antigenic peptide for the four structures in 
the overlay. HLA residues closer than 6 Å from TCR are highlighted in a ball-and-stick 
representation. 
 
To evaluate the stability of the computational simulations (reliability of the 
simulations), the evolution of the structures along the trajectories was calculated 
(Figure 12). The evolution of the structures along the trajectories is displayed by the 
root mean-squared deviation (RMSD) values with respect to the initial structures.   
 
Figure 12. Time courses for the Root Mean Square Deviations along the simulations. 
RMSDs were calculated for the main-chain atoms, using the initial, energy minimized 
structure as reference. 
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In agreement with the statistical data in Table 1, the structure of the distinct pHLA 
binary complexes barely changes along simulations. Hence, comparing the average 
structures of HLA bonded to reactive and non-reactive peptides reveals that they are 
highly similar. The RMSD values observed for the ternary complexes (pHLA-TCR) 
are marginally larger, but still not significant when considering that it is a complex 
involving 3 large polypeptides and the antigen oligopeptide.  
Both, protein unfolding and complex dissociation are accompanied by an increase of 
the RG values of the protein component of the simulated system. Hence, the radii of 
gyration (RG) were also monitored along the computations. The initial RG values for 
binary and ternary complexes were 17 Å and 30 Å, respectively. The absence of any 
increment or fluctuation in RG values along the trajectories clearly indicates that the 
oligopeptides remain bonded to the HLA domain in all the calculations. In other 
words, the trajectories were stable and reliable along the simulations. 
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1.3. Effect of the peptide in HLA structure 
Next, we studied the effect of the presence of the peptide in HLA structure. The 
slightly larger RMSD values observed for the free HLA trajectory (2.65 Å on average) 
suggest that a small structural change takes place. In fact, the gyration radius of free 
HLA is smaller (15.22 Å) than those of the various pHLA complexes (ca. 17.2 Å). 
Indeed, the α-helical regions of free HLA relax and approach each other due to the 
absence of the antigenic peptide in the cleft they define. 
The differences between the pattern of atomic fluctuations within HLA in its free and 
binary (pHLA) forms are shown in Figure 13A. A positive value indicates a greater 
mobility of a residue in pHLA with respect to free HLA. As expected, the values were 
negative in the α-helix regions that define the groove of HLA housing the antigen. 
Thus, their mobility decreases when they clamp the antigenic peptide. In particular, 
the fluctuations of α helices 2 and 3 resulted to be more sensitive to the presence of 
the antigen than α helix 1. In fact, the hinge between these two elements is highly 
restrained by the oligopeptide. 
When checking the root mean square fluctuations (RMSFs) of the binary pHLA 
complexes, t-student tests showed no difference between TAX-HLA and V7R-HLA 
complexes. However, P6A-HLA and Y8A-HLA showed a slight but significant 
increase of the average backbone fluctuations (Figure 13B), according to t-student 
tests at 5% confidence. In fact, although the pattern of fluctuations barely changed in 
the various pHLA complexes, there were differences in specific residues related to 
the reactivity of the peptide bound to HLA (Figure 13B,C). For instance, the region 
comprising the amino acid at positions 38–48 and 100–110 fluctuated more in the 
non-reactive than in the reactive complexes. Notably, Trp107 shows the largest 
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fluctuations in non-reactive P6A-HLA and Y8A-HLA. Trp107 sidechain is in close 
contact with α helix 3, which is involved in TCR binding. 
 
Figure 13. Root mean square fluctuations (RMSF) of HLA in the different complexes.  
A) Differences between main-chain fluctuations of HLA in its free and binary forms, pHLA. 
Data corresponding to TAX-HLA, V7R-HLA, P6A-HLA and Y8A-HLA are in red, orange, blue 
and green, respectively. Secondary structure elements are shown on top of the abscissa 
axis. Blue arrows represent β-strands and helical regions (α in red, π in orange) are shown 
as boxes. B) Backbone fluctuations within V7R-HLA, P6A-HLA and Y8A-HLA complexes 
relative to the TAX-HLA complex. The N-terminus of the α-helix 1 and the central turns of the 
α-helix 3 present larger fluctuations (red) in the P6A-HLA and Y8A-HLA complexes than the 
reactive complex. C) Maps of the main-chain RMSD differences between the mutant binary 
complexes and TAX-HLA. Colors scales from -1.2 Å (blue) to 1.5 Å (red). 
 
Nevertheless, the largest differences locate at loops out of the surface patch of pHLA 
that contacts TCR. Taking the wild-type TAX-HLA reactive complex as a reference, 
we examined the fluctuations of the non-reactive and weakly reactive V7R-HLA, P6A-
HLA and Y8A-HLA complexes (Fig 13B,C). However, data reveals a slight 
enhancement of fluctuations of the N-terminus region of α-helix 1, whereas the C-
terminus of α-helices 2 and 3, the hinge region between these two elements and 
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Gly162, which locates at the π-helix region in the middle of helix 3, decrease their 
mobility. 
 
1.4. Effects of TCR binding on pHLA dynamics 
We next sought to study the effect of TCR binding on pHLA dynamics. Interestingly, 
binding to the TCR hardly affects the structure of pHLA. In fact, the average RMSD of 
the binary reactive complex TAX-HLA is nearly identical (1.36 Å) to its average value 
computed in the ternary reactive complex TAX-HLA-TCR (1.33 Å). The average 
RMSD values of the non-reactive and weakly reactive complexes were also below 2 
Å, though they were higher in the ternary complexes than in their respective binary 
forms (Table1). 
To test the internal mobility within the various molecules, we analyzed the atomic 
fluctuations (RMSFs) of the main-chain atoms. The pattern of TCR fluctuations was 
very similar in the different complexes (data not shown). Notably, pHLA binding 
barely restrains the TCR motions besides those of the CDR3 loops responsible for 
the molecular recognition of the pHLA molecules, and some flexible loops located at 
the constant α and β domains. Upon TCR binding, HLA displays an overall drop in its 
backbone fluctuations (data not shown), according to t-student tests at 1% 
significance–p values being lower than 10−8. In addition, a specific loss of mobility 
was found for the unreactive pHLA complexes in the stretch comprising amino acids 
85 to 92, which corresponds to the loop joining α-helix 1 to β-strand 4.  
Hence, to investigate to which extent the differences in the atomic fluctuations may 
affect the binding equilibrium, we calculated the contribution of conformational 
(vibration) entropy (ΔSconf) of free TCR, binary and ternary complexes and then of the 
association following the cycle ΔSconf ternary− ΔSconf freeTCR− ΔSconf binary.  
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Data in Table 2, computed using all the protein atoms, indicate that vibrational 
entropy contribution is less favorable for the formation of ternary complexes involving 
non-reactive antigens, in agreement with the slightly higher fluctuations found in their 
binary complexes. In other words, these differences in conformational entropy are 
related to the higher pHLA entropy in the binary non-reactive pHLA complexes and 
the smaller entropies found in the non-reactive ternary ones. 
 
 
 
To summarize, analysis at atomic level revealed that the binary non-reactive 
complexes (P6A-HLA and Y8A-HLA) show higher fluctuations than the reactive 
complex (TAX-HLA), therefore the formation of ternary complexes involving non-
reactive antigens is less favorable.  
 
1.5. Salt-bridge patterns and electrostatics 
To evaluate the stability of the interaction pHLA and TCR, salt bridges and 
electrostatics were calculated. The salt bridges were studied in all the trajectories of 
the different binary and ternary complexes (Figure 14), considering ion-pairs with an 
oxygen-nitrogen distance lower than 3.2 Å in the peptide-HLA-TCR interface. 
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Figure 14. Salt bridges in binary complexes.  
A) Patterns of salt bridges in the binary complexes, pHLA. The normalized weight 
(proportional to the inverse of the distance between the heavy atoms of the two charged 
groups) of each salt bridge is represented as a grey scale from 0 (white) to 0.35 (black). B) 
Representation of the TAX-HLA binary complex structure. Residues involved in salt bridges 
are represented in sticks. Labeled, black-colored residues are involved in salt bridges that 
are lost in non-reactive pHLA complexes.  
 
Regarding the pHLA binary complexes, we observed ten salt bridges in TAX-HLA, six 
in V7R-HLA, eight in P6A-HLA and seven in Y8A-HLA (Figure 14A). These salt 
bridges are intramolecular interactions between charged groups of HLA. The 
electrostatic potential energy for a given pair of charges is inversely proportional to 
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the distance between them, so we calculated the average of the inverse of the 
distances of every salt bridge during the trajectory of the complexes. The resulting 
data were represented as a matrix for the four pHLA complexes. The observed 
patterns in these matrices varied between them. Notably, the weakly reactive and 
non-reactive complexes had fewer salt bridges than the reactive one, agreeing with 
fluctuations results. The pattern of the weakly reactive complex (V7R-HLA) is 
intermediate between the patterns of the reactive (TAX-HLA) and non-reactive (P6A-
HLA, Y8A-HLA) complexes. In fact, five salt bridges were common to all complexes 
(Asp61-Arg65, Glu154-Arg157, Glu55-Arg170, Glu166-Arg170 and Asp77-Arg97). In 
contrast, we noted the absence of three salt bridges from the non-reactive complexes 
(Glu148-Arg131, Glu154-Arg131 and Asp137-Lys121) that were present in the 
reactive complex (TAX-HLA). These salt bridges involve residues from α helices 2 
and 3, and the rim of the β-sheet (Figure 14B). They may restrain the motion of these 
two helices in the reactive complexes, thereby favoring the interaction with TCR. In 
conclusion, we observed a signature salt bridge pattern in the peptide-HLA 
complexes that varied according to the reactivity of the complex. This pattern is 
consistent with the distinct backbone fluctuation profiles. 
 
We next analyzed the salt bridges formed at the pHLA-TCR interface (Figure 15A). 
As observed within the binary pHLA complexes, we noted a significant loss of salt 
bridges in the non-reactive ternary complexes relative to the reactive complex. In 
particular, the reactive complex TAX-HLA-TCR had thirteen salt bridges; the 
intermediate complex V7R-HLA-TCR had ten, and the non-reactive complexes P6A-
HLA-TCR and Y8A-HLA-TCR had five and seven salt bridges, respectively. 
Accordingly, the number of intermolecular salt bridges between pHLA and TCR was 
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also lower. The reactive complex had six intermolecular salt bridges whereas the 
intermediate complex had five and the non-reactive complexes P6A-HLA-TCR and 
Y8A-HLA-TCR had two and four intermolecular salt bridges, respectively. This may 
explain in part why the interaction between HLA and TCR is weaker in these 
complexes than in the reactive ones. 
 
Figure 15. Salt bridges in ternary complexes.  
A) Pattern of salt bridges in the ternary complex, pHLA-TCR. TCR residues are in bold font, 
and with a Greek letters indicating the chain to which the residue belongs. Arrows point to 
HLA-TCR intermolecular bridges. B) Detail of the structure of the TAX ternary complex (pdb 
code: 1ao7), displaying in sticks the antigen (in white) as well as the residues involved in 
intermolecular HLA-TCR salt bridges (in black). Bold font labels correspond to residues from 
TCR, plain font ones to HLA. 
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We noted an absence of seven salt bridges in the weakly reactive and non-reactive 
complexes. Three of these are intermolecular between HLA and TCR (Glu154 of HLA 
with Arg102 of the chain β of TCR, Glu154 of HLA with Lys55 of chain α of TCR, 
Glu55 of HLA with Arg27 of chain α of TCR). The two first are lost in the non-reactive 
complexes: those involving P6A and Y8A. Three salt bridges modulated the mobility 
of α helix 3 of HLA (Glu19-Arg75, Glu161-Arg157 and Glu166-Arg169). This may 
account also for the differences in vibrational entropies mentioned above. In addition, 
we found five salt bridges to be present in all complexes (Asp77 with Arg97 of HLA, 
Glu55 with Arg170 of HLA, Glu63 with Lys66 of HLA, Arg65 of HLA with Asp95 of the 
α-chain of TCR and Glu166 of HLA with Lys68 of the α-chain of TCR), thus 
suggesting them to be conserved and well-organized. In the V7R-HLA-TCR complex, 
six salt bridges were lost, whereas three new ones were gained. One of them 
involves residues from both HLA (Lys66) and TCR (Asp95). In the Y8A-HLA-TCR 
complex, only one new salt bridge was gained, and this was the same as that 
observed in the V7R-HLA-TCR complex (Lys66 of HLA with Asp95 of the α chain of 
TCR). In conclusion, we observed a signature salt bridge pattern in the ternary 
peptide-HLA-TCR complexes that differed in its reactive complex compared with 
weakly reactive and non-reactive ones. 
To quantify these salt bridge signatures, we calculated the Frobenius’ distances 
between the matrixes representing the distinct patterns (Table 3). This parameter 
measures how different two matrices of the same dimensions are. The larger the 
distance is, the more different are the two compared matrixes. Clearly, non-reactive 
ternary complexes are more similar to each other with respect their salt bridge 
pattern than they are to the reactive form. This trend is less pronounced in the binary 
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complexes and more noticeable when only the intermolecular HLA-TCR salt bridges 
are considered. 
 
 
 
Finally, we studied how the change in the salt bridges affects the electrostatics of the 
various binary complexes (Figure 16). A single amino acid substitution in a peptide 
affects the electrostatic potential of the complex even if it does not modify the charge 
of the peptide, as is the case with the P6A-HLA and Y8A-HLA complexes. As the 
oligopeptide is held in a cleft, the mutations may affect pHLA solvation and the 
boundary between two phases with different dielectric constants: the protein and the 
solvent. In its turn, these changes may affect how the charged residues interact at 
the protein surface. Nevertheless, in the complex V7R-HLA, the substitution modifies 
the charge, since a non-polar amino acid (valine) is replaced by a polar amino acid 
(arginine) at position seven. We observed that positive regions were strongly 
attenuated by this substitution. Surprisingly, this also occurred in the non-reactive 
complexes, even without a change of charge. 
 
These studies have already been published (García-Guerrero E et al.; PLoS One. 
2016 Apr 28;11(4):e0154219. doi: 10.1371/journal.pone.0154219) 
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Figure 16. Electrostatics of the pHLA binary complexes.  
Electrostatic potential maps at the surface of WT and mutant pHLA binary complexes. Color 
scales from dark blue (10 kJ mol-1 e-1) to dark red (-10 kJ mol-1 e-1). The electrostatic grids 
were calculated using DelPhi software. Protein dielectric constant was set to 4. 
 
In conclusion, the pHLA-TCR interactions that involve immune reactive peptides are 
more stable and strong than those which do not induce a triggering of the TCR 
activation. In our model, the stabilization of the reactive TAX-HLA-TCR complex was 
achieved due to less fluctuations and more salt bridges comparing with non-reactive 
peptides. In aggregate, these results support our hypothesis that tumor-reactive T 
cells may form strong interactions with tumor cells. Consequently, our next point was 
to take advantage of the strength of these interactions to develop a new method to 
obtain CTLs from AML patients through FACS-based cell sorting. 
 
Strategies to Obtain Tumor-reactive Cells                                                           RESULTS 
 
 
 
113 
2. The Basics of “Doublet Technology”: Co-Culture Conditions, 
Incubation Time and FACS-Based Cell Sorting 
 
Therapies using tumor infiltrating lymphocytes (TILs) have made great progress in 
the treatment of solid tumors, especially melanoma (Rosenberg et al., 1994; Dudley 
et al., 2008). We aimed to transfer this therapeutic approach to the treatment of 
hematologic malignancy. Therefore, we strived to obtain tumor-reactive CTLs from 
AML patients to subsequently use them for autologous adoptive cell transfer therapy. 
To achieve this goal, we began by performing co-cultures of two different healthy 
donors to set up the best conditions to identify and select those T cells which 
recognize and bind the target cell (doublet T cells). 
 
2.1. Co-culture conditions 
We first checked the possibility to identify doublet T cells by flow cytometry indicating 
a T cell-target cell complex. To this end, co-cultures between donor 1 (Donor) and 
donor 2 (Target) were performed. T cell-depleted target PBMC were stained with 
PKH-67 (CD3-PKH+PBMC) to differentiate them from the donor´s PBMC (Figure 
17A). Furthermore, T-cell depletion in the target fraction allowed a better activation of 
donor´s T cells (Figure 17B) (n=4, p=0.005 for CD25; p=0.003 for CD69). Moreover, 
target CD3-PKH+PBMC were irradiated to avoid the immune response of these cells 
against donor ‘s cells. Thereby, our cellular model allows us to study the response of 
donor´s T cells against target cells.  
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Figure 17. Schedule of the procedure and T cell activation.   
A) PBMC from two healthy donors were obtained by density gradient centrifugation. Target 
PBMC were depleted of CD3 cells, irradiated and stained with PKH-67 (CD3-PKH+PBMC). 
Co-cultures of donor´s PBMC and target CD3-PKH+PBMC were performed. B) T cell 
activation markers (CD25 and CD69) were analyzed after 48h of co-culture. Shown are 
mean ±SD of four independent experiments. P values between the indicated groups were 
calculated using paired Student t tests.  
 
Then, we performed co-cultures at donor:target cell ratio of 3:1 and analyzed them by 
flow cytometry. Doublet-forming T cells were identified as a population that shows a 
higher FSC/SSC and express simultaneously CD3 and PKH. Thus, the doublet 
positive cells (CD3+PKH+) consist of CD3+ T cells from donor bound to PKH-stained 
target cells (Figure 18A). Furthermore, the doublet T cells were also identified under 
confocal microscope (Figure 18B). The monitoring of co-cultures was performed 
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within 15 hours using the incubator integrated with a confocal microscope and a 
camera. Hence, we could observe that CTLs bind target cells (green for the PKH 
emission) and form doublet cells (data not shown).   
 
Figure 18. Identification by flow cytometry of the doublet cells.   
A) Identification of doublet T cells. Co-cultures of donor´s PBMC and target CD3-
PKH+PBMC were performed. After 20h of co-culture, cells were directly stained and 
harvested for flow cytometry analyses. A population with higher FSC/SSC, CD3+ and PKH+ 
was gated. B) The co-cultures were also analyzed under confocal microscope at different 
time points (2, 6, 12, 24 h) and the doublet-forming T cells were observed.   
  
2.2. Incubation time 
After identifying the doublet positive cells as a population which demonstrates higher 
FSC/SSC distribution and the expression of CD3 and PKH, we explored the optimal 
incubation time to obtain the highest proportion of doublet-forming T cells. 
Strategies to Obtain Tumor-reactive Cells                              
 
 
 
 
116 
Consequently, we performed co-cultures and analyzed at different time points by flow 
cytometry the percentage of doublet population. The time point of 15 hours resulted 
in highest doublet percentage (Figure 19).  
 
Figure 19. Time course of the co-culture. 
Co-cultures of donor´s PBMC and target CD3-PKH+PBMC were incubated in 48 well plates 
for 5, 15, 24 and 48 hours. After each time point, cells were directly stained and harvested for 
flow cytometry analyses. Representation of the percentage of doublet T cells vs co-culture 
time (hours) is shown. Depicted are the mean ± SD of three independent experiments.  
 
Once the doublet population was identified and the optimal time of co-culture was 
determined, we continued to select this population through cell sorting.  
 
2.3. FACS-based cell sorting 
Co-cultures of donor´s PBMC and CD3-depleted, PKH-stained target PBMC (CD3-
PKH+PBMC) were performed. After 15h of incubation, the cells were stained for the 
following panel: CD25-PE/CD3-APC/CD45-PB. Afterwards, the cells were washed 
and sorted based on their FSC/SSC as well as their positivity for both CD3 and PKH 
(doublet-forming T cells). The FACS Aria Fusion Cell Sorter was run with an 85 µm 
nozzle for sorting the doublet positive cells due to their large size and higher 
sensitivity (T cell bound to a target cell).  
Doublet-forming T cells were identified in a range of 3% to 6% (n=10). The selected 
populations CD3+PKH+ (doublet T cells) and CD3+PKH- (non-doublet T cells) were 
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further characterized. Within this last fraction, two populations were identified by the 
following phenotypes: CD3+PKH-CD25- and CD3+PKH-CD25+ (Figure 20).  
 
Figure 20. Sorting of doublet cells and non-doublet cells. 
Co-cultures of donor´s PBMC and target CD3-PKH+PBMC were performed at a ratio of 3:1 
for 15h. After incubation, cells were stained, harvested and filtrated. Doublet population (high 
FSC/SSC, CD3+PKH+) and non-doublet cells (low FSC/SSC, CD3+PKH-) were identified 
and sorted.   
 
After the sorting procedure, cells were analyzed by flow cytometry and observed 
under confocal microscope. The doublet T cells (CD3+PKH+) were still forming 
doublet positive population (>90%, n=3) and the non-doublet populations, both 
CD3+PKH-CD25+ and CD3+PKH-CD25-, were also highly purified (>95%, n=3).  
 
Figure 21. Purification of doublet cells and non-doublet cells by cell sorting.  
Doublet positive population (CD3+PKH+) and non-doublet cells (CD3+PKH-) were identified 
and sorted after 15h of the co-culture. The isolated cells were checked by flow cytometry 
after the sorting procedure.  
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3. Doublet T Cells Show Higher Percentage of Effector Cells and 
Specific Cytotoxic Activity as Compared to Non-Doublet T Cells  
 
3.1. Immunophenotype of doublet T cells vs non-doublet T cells  
Immunophenotyping analysis demonstrated the difference between doublet-forming 
T cells (CD3+PKH+) and the T cells which did not form stable and strong interactions 
with target cells (CD3+PKH-CD25-). To compare the phenotype of both populations, 
we performed co-cultures for 15h. At this time point, cells were stained with the 
following panel: PKH-FITC/CCR7-PE/CD3-PerCP/CD45RA-PECy7/CD8-APC/CD4-
APCCy7/CD45-PO. Thereby, we studied not only the CD4+/CD8+ ratio, but also the 
percentage of T cell-subtypes. The T cell-subtypes were characterized by expression 
of CD45RA and CCR7 following the next criterion: Naïve (CD45RA+CCR7+), Effector 
(CD45RA+CCR7-), Central memory (CD45RA-CCR7+) and Peripheral memory 
(CD45RA-CCR7-) (Figure 22).  
 
Figure 22: Immunophenotype of doublet and non-doublet cells.  
Co-cultures of donor´s PBMC and target CD3-PKH+PBMC were performed. Cells were 
evaluated by flow cytometry (n=6). Dot plots show CD4, CD8, CD45RA and CCR7 
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expression on doublet T cells (upper panel) and non-doublet T cells (bottom panel). Within 
CD4+ and CD8+ cells, naïve (CD45RA+CCR7+), effector (CD45RA+CCR7-), central 
memory (CD45RA-CCR7+) and peripheral memory (CD45RA-CCR7-) T cells were analyzed. 
The Infinicyt software was used for data analysis.  
  
 
Comparing doublet-forming T cells with non-doublet T cells, we could find differences 
regarding to the ratio CD4+/CD8+. As shown in figure 23A, doublet T cells showed a 
higher percentage of CD8+ T cells, while non-doublet T cells showed a higher 
percentage of CD4+ T cells. Within CD4+ T cells, similar percentage of naïve, central 
memory and peripheral memory between doublet cells and non-doublet cells was 
observed. The same result was noted in CD8+ T cells. However, different percentage 
of effector CD4+ and CD8+ T cells was observed when doublet cells were compared 
with non-doublet cells (Figure 23B, C).  
 
Figure 23: Percentage of T cell-subtypes in doublet and non-doublet cells.  
A) Percentage of CD4+, CD8+, CD4+/CD8+ and CD4-/CD8- cells in doublet cells compared 
to non-doublet cells. B) Regarding CD4+ T cells, the percentage of naïve 
(CD45RA+CCR7+), effector (CD45RA+CCR7-), central memory (CD45RA-CCR7+) and 
peripheral memory (CD45RA-CCR7-) T cells is shown. The same analysis is shown in C) for 
CD8+ cells. Data show mean values of six independent experiments. 
 
Accordingly, there was a significant difference in the percentage of CD4+ and CD8+ 
cells between doublet-forming T cells and non-doublet T cells (Figure 24A) (n=6, 
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p<0.001). Furthermore, the percentage of effector CD4+ and CD8+ was significantly 
higher in doublet population (Figure 24B,C) (n=6, p<0.001 for effector CD4+; p<0.05 
for effector CD8+). No significant differences were observed between the proportions 
of naïve, central memory or peripheral memory subtypes between both groups (n=6).  
 
Figure 24: Statistic analyses of T cell-subtypes. 
A) Percentage of CD4+ and CD8+ cells in doublet population vs non-doublet population. The 
mean percentage of CD4+ cells in doublet and non-doublet population was 25.73% vs 
65.42%, respectively. The mean percentage of CD8+ cells in doublet and non-doublet 
population was 50.86% vs 23.42%, respectively. Percentage of effector CD4+ cells (B) and 
effector CD8+ cells (C) is shown. The mean percentage of effector CD4+ cells in doublet and 
non-doublet population was 5.57% vs 1.47%, respectively.  Regarding effector CD8+ cells, 
the mean percentage comparing doublet and non-doublet population was 19.57% vs 
12.43%, respectively. Depicted are the mean ± SD of six independent experiments. P values 
between the indicated groups were calculated using paired Student t tests. 
 
Finally, doublet T cells were negative for γδ expression suggesting that they present 
the αβ phenotype. A small proportion of γδ T cells were identified in the population of 
non-doublet T cells (data not shown). 
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3.2. Cytotoxic activity of doublet T cells vs non-doublet T cells  
The cytotoxic effect of doublet-forming T cells (CD3+PKH+) was analyzed and 
compared to non-doublet T cells (CD3+PKH-CD25-) in secondary co-cultures (Figure 
25). Thus, the sorted populations were again co-cultured with target cells. Therefore, 
doublet T cells (CD3+PKH+) as well as non-doublet T cells (CD3+PKH-CD25-) were 
washed and rested for at least 20h after sorting. During this time, doublet-forming T 
cells became single T cells due to the elimination of the target cells. CD3-depleted 
target PBMC were thawed and stained with PKH-67 (CD3-PKH+PBMC). Secondary 
co-cultures between doublet-forming T cells from donor and target CD3-PKH+PBMC 
were performed. Of note, target cells in secondary co-cultures were not irradiated in 
order to analyze the cytotoxic effect of donor´s T cells.  
 
Figure 25: Schedule of the procedure with buffy coats.  
PBMC from donor were co-cultured with target PBMC depleted of CD3 cells, irradiated and 
stained with PKH-67 (first co-culture). After 15h, cells were stained with CD3, CD45 and 
CD25 antibodies for cell sorting. Doublet positive cells (CD3+PKH+) and non-doublet cells 
(CD3+PKH-) were sorted and rested for 20h. Target cells were thawed and stained with 
PKH-67 and secondary co-cultures between doublet-forming T cells or non-doublet T cells 
with target cells were performed (second co-culture). After 7 hours, cells were collected and 
stained with 7AAD and Annexin V. 
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Live target cells were determined by flow cytometry as a 7AAD and Annexin V 
negative population. The cytolytic activity was evaluated comparing the viability of 
target cells cultured alone or with doublet-forming T cells or non-doublet T cells.  
As shown in figure 26A, significant increase of the specific lysis of target cells was 
obtained when doublet T cells were co-cultured compared to non-doublet T cells 
(n=6, p=0,0029). Further, we developed secondary co-cultures to analyze the CD69 
activation marker after 24h of the co-culture (Figure 26B). A high percentage of 
CD69+ cells was observed in co-cultures with doublet-forming T cells against target 
cells compared to non-doublet T cells. When the activation was achieved using anti-
CD3/anti-CD28 antibodies, the percentage of CD69+ cells was even higher indicating 
that the activation against target cells was specific.  
 
Figure 26: Functional assays of doublet-forming T cells vs non-doublet T cells.    
A) Specific lysis of doublet-forming T cells. Secondary co-cultures between doublet-forming T 
cells or non-doublet T cells with target cells were performed. After 7 hours, cells were 
collected and stained with 7AAD and Annexin V. The specific lysis was calculated following 
the next formula: [(target viability alone–target viability with doublet or non-doublet T cells)/ 
target viability alone] x100. Data show mean values ± SD of six independent experiments. B) 
CD69 expression on secondary co-cultures. After 24 hours of co-culture, cells were analyzed 
by flow cytometry. Data show mean values ± SD of three independent experiments. P values 
between the indicated groups were calculated using paired Student t tests.  
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4. A Subset of Non-Doublet T Cells Have Immuno-Suppressive 
Function 
4.1. Immunophenotype of non-doublet T cells  
Non-doublet T cells (CD3+PKH-) were sorted based on their CD25 expression. 
Regarding the CD25+ T cells (CD3+PKH-CD25+), they showed regulatory phenotype 
expressing CD4, FoxP3 and CD25, but not CD127, thus suggesting that they are 
regulatory T cells (Figure 27) (>95%, n=6). The immunophenotype of non-doublet T 
cells that do not express CD25 (CD3+PKH-CD25-) was already shown in section 3. 
 
Figure 27: Immunophenotype of non-doublet cells CD3+PKH-CD25+. 
The regulatory phenotype was evaluated in non-doublet T cells that express CD25. Dot plots 
show the expression of CD4, CD25, FoxP3 and CD127 on non-doublet T cells CD25+ 
(CD3+PKH-CD25+). Data show one representative experiment of six independent 
experiments. 
 
4.2. Immuno-suppressive function of non-doublet T cells 
Next, we investigated whether these non-doublet regulatory T cells showed 
suppressive capacity using functional assays. For this purpose, freshly isolated PKH-
67 stained T cells (effector T cells) were stimulated with anti-CD3 and anti-CD28 
antibodies and co-cultured with non-doublet regulatory T cells. As controls, effector T 
cells were cultured alone, either unstimulated or stimulated with anti-CD3/anti-CD28.  
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Moreover, freshly isolated CD4+CD25+ Treg cells and T cells depleted of Treg were 
used as controls. For that purpose, PBMC from a healthy donor were isolated. The 
CD4+CD25+ Treg cells were obtained by positive magnetic selection, and the 
negative fraction was used as T cells depleted of Treg. Furthermore, we were 
interested in studying the suppressive function of the population CD3+PKH-CD25-. 
Afterwards, escalating ratios of both non-doublet T cells:effector T cells were 
performed in order to evaluate the suppressive capacity of these cells. After four days 
of co-incubation, we analyzed the proliferation of effector T cells (Figure 28). 
 
Figure 28: Titration of suppression capacity.  
The percentage of proliferating effector T cells monitored by PKH-67 dilution is shown. 
Titration assays showing the suppressive capacity of non-doublet T cells (CD3+PKH-CD25+ 
and CD3PKH-CD25-) at increasing ratios of non-doublet cells cultured versus effector T 
cells. Naturally occurring CD4+CD25+ Treg as well as T cells depleted of nTreg were used 
as controls. The proliferation of αCD3/αCD28 stimulated effector T cells was used as 
baseline.  
 
The number of proliferating cells, as assessed by PKH fluorescence diminution, 
significantly decreased when co-incubated with non-doublet regulatory T cells 
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(CD3+PKH-CD25+) (n=3, p=0.0369 for ratio 1:2; p=0.0150 for ratio 1:1). Surprisingly, 
non-doublet CD25- T cells (CD3+PKH-CD25-) also showed suppressive function 
(n=3, p=0.0058 for ratio 1:2; p=0.0151 for ratio 1:1). Accordingly, the CD25 activation 
marker expression was also significantly decreased when non-doublet regulatory T 
cells or non-doublet CD25- T cells were co-incubated with effector T cells (Figure 29).  
 
Figure 29: Suppression capacity assays.  
The percentage of proliferation (left bar diagram) and CD25 expression (right bar diagram) of 
effector T cells is shown. Proliferation was assessed by PKH fluorescence using ModFit 
software. PKH and CD25 expression were analyzed by flow cytometry. Depicted are the 
mean ± SD of three independent experiments. P values between the indicated groups were 
calculated using paired Student t tests. 
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5. Clinical Application: Doublet T Cells from AML Patients Have 
Specific Cytotoxic Activity against Primary Blast Cells 
TIL from metastatic melanoma lesions comprise an enriched source of tumor-antigen 
reactive cells (Dudley et al., 2008). Therefore, co-cultures of T cells from AML 
patients and autologous tumor cells were performed in order to obtain naturally 
occurring tumor-reactive T cells.  
 
5.1. Patient samples 
Bone marrow (BM) samples were obtained from patients with relapsed/refractory 
AML. The percentage of tumor cells in the BM samples was >90% in all cases 
(Figure 30A). After the treatment, patients with <5% blasts in the BM, recovery of 
neutrophils and platelets, and absence of extramedullary disease were considered in 
complete remission status (Figure 30B).  Under this criterion, PBMC from AML 
patients in CR were obtained and co-cultured with PKH-67 stained and irradiated 
autologous tumor cells. After 15h of co-incubation, cells were stained and harvested 
for sorting. Doublet-forming T cells from AML patients were identified in a range of 
2% to 6% (Figure 30C) (mean=3.83%, n=5). 
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Figure 30: Doublet-forming T cells from an AML patient. 
A) Blast cells from bone marrow of AML patient were obtained and frozen. The tumor sample 
contained 92% of blasts. The immunophenotype of blast cells were: CD45low CD34++, CD38+, 
HLA-DR+. B) PBMC were obtained from peripheral blood when the patient was in CR and 
analyzed by flow cytometry. T cells represented the 46% of the total PMBC. C) T cells from 
the patient were co-incubated with blast cells for 15h. Then, cells were stained and sorted. 
Doublet-forming T cells were identified based on their FSC/SSC characteristics as well as 
their positivity for both PKH and CD3 (green). Non-doublet T cells were also isolated to use 
them as control (red). One representative case is shown. 
 
5.2. Cytotoxic activity of doublet T cells against blast cells 
Next, the sorted doublet-forming T cells and non-doublet T cells were cultured 
overnight. Tumor cells from the same patient (autologous tumor cells) were thawed 
and stained with PKH-67 or specific CD markers based on the immunophenotype at 
diagnosis. Secondary co-cultures of doublet-forming T cells and non-doublet T cells 
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with autologous tumor cells were performed for 7 hours (Figure 31). Of note, tumor 
cells were not irradiated in order to analyze the cytotoxic effect of doublet-forming T 
cells from the patient. To determine the cytotoxic activity of doublet-forming T cells, 
the tumor viability was analyzed by flow cytometry using 7AAD and Annexin V 
staining.  
 
Figure 31: Schedule of the procedure performed with tumor samples. 
Tumor cells and PBMC from AML patients were obtained. Tumor cells were irradiated at 
25Gy and stained with PKH-67. Co-culture of PBMC and tumor cells from the same patient 
was performed for 15 hours (first co-culture). Then, cells were stained and harvested for cell 
sorting. The sorted populations (CD3+PKH+ and CD3+PKH-) were maintained resting 
overnight. Autologous tumor cells were thawed and stained with PKH-67 or specific CD 
markers. Secondary co-cultures between doublet-forming T cells or non-doublet T cells with 
autologous tumor cells were performed (second co-culture). After 7 hours, cells were 
collected and stained with 7AAD and Annexin V. 
 
The cytolytic activity was evaluated comparing the viability of tumor cells cultured 
alone or with doublet-forming T cells or non-doublet cells from the same patient. As 
shown in figure 32A, significant increase of the specific lysis of tumor cells was 
obtained when doublet T cells were co-cultured compared to non-doublet T cells 
(p=0,0424 ; n=3).  
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Figure 32: Specific lysis of doublet-forming T cells against tumor cells. 
Secondary co-cultures between doublet-forming T cells or non-doublet T cells with tumor 
cells from the same patient were performed. After 7 hours, cells were collected and stained 
with 7AAD and Annexin V. Viable cells were negative for both 7AAD and Annexin V. A) The 
specific lysis was calculated following the next formula: [(tumor viability alone–tumor viability 
with doublet or non-doublet cells)/ tumor viability] x100. Data show mean values ± SD of 
five independent experiments. B) The viability ratio was calculated as follows: 1-[(tumor 
viability alone–tumor viability with doublet or non-doublet cells)/ tumor viability alone]. For 
secondary co-cultures, different staining of tumor cells was used. Tumor cells were stained 
with PKH-67 (n=3) or specific tumor CD marker (n=2). The viability ratio after co-cultures 
between doublet-forming T cells or non-doublet T cells with PKH-67 stained tumor cells (C) 
or CD marker stained tumor cells (D) are shown. P values between the indicated groups 
were calculated using paired Student t tests. 
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We also calculated the viability ratio and a significant difference between doublet-
forming T cells and non-doublet T cells was observed (Figure 32B). Regarding the 
secondary co-cultures, tumor cells were also stained with tumor specific CD markers 
based on the immunophenotype of the AML at diagnosis instead of PKH-67 to 
analyze the tumor viability after co-cultures (n=2). The cytolytic activity of doublet-
forming T cells against tumor cells in secondary co-cultures was observed in both 
conditions, PKH-67 or CD marker stained tumor cells (Figure 32C,D). Hence, we 
were able to obtain tumor-reactive T cells from AML patients by “Doublet 
Technology”. 
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6. Interim Conclusion for “Doublet Technology” 
In this study, our first objective was to analyze the interaction between the TCR and 
pMHC complex and to identify/isolate natural autologous tumor-reactive T 
lymphocytes from acute myeloid leukemia (AML) patients through FACS-based cell 
sorting. 
We aimed to address several limitations related to the isolation of tumor-specific 
CTLs using conventional strategies, such as cytokine production assay or soluble 
pMHC multimers: 1) Selection of CTL based on cytokine production assays does not 
exclusively represent functional cytotoxicity. 2) In order to use this approaches the 
target antigen must be well known, which is not the case for most tumor cells.  
We hypothesized that tumor-reactive T cells may form strong interactions with tumor 
cells trough TCR so that they could be identified and isolated by our “Doublet 
Technology” to pull out naturally occurring tumor-specific CTLs in hematologic 
malignancies. 
In summary, our data demonstrate that pHLA-TCR interactions that involve immune 
reactive peptides are more stable and strong than those which do not induce a robust 
triggering of the TCR. Moreover, we observed that when T cells from AML patients 
are co-cultured with tumor cells, a doublet population appears. This population 
consists of T cells bound to tumor cells. We have shown that CTLs bound through 
TCR to tumor cells can be selected and isolated through FACS-based cell sorting. 
The CTLs from AML patients obtained with this technique have shown cytolytic 
activity against blast cells from AML patients suggesting the clinical use of these 
CTLs. Further, not only CD8+ tumor-reactive T cells are isolated with this approach, 
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but also CD4+ effector T cells. Finally, the “Doublet Technology” represents a very 
useful advantage in cancer immunotherapy because it is not required a prior 
knowledge of the exact tumor antigen. Therefore, we are able to obtain tumor-
specific T cells from each patient offering a personalized therapy. 
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PART II 
 
 CAR TECHNOLOGY TO GENERATE  
TUMOR-REACTIVE T CELLS 
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The second objective of this study were to genetically modify T lymphocytes with 
chimeric antigen receptors (CARs) to redirect autologous T cells against a specific 
tumor antigen expressed on the surface of tumor cells and to confirm their anti-tumor 
reactivity. In particular, we generated a second generation CAR against the B-Cell 
Maturation Antigen (BCMA) by genetic modification of T cells to target BCMA-
expressing malignant plasma cells of multiple myeloma (MM) patients.  
Therefore, we first designed two CAR constructs consist of two different recognition 
domains (BCMA 30 and BCMA 50) against the same epitope of BCMA. Furthermore, 
we designed each CAR construct in two different versions (short and long) to study 
the effect of the CAR design in the functionality. Moreover, we analyzed the serum 
from patients and determined whether the presence of soluble BCMA protein could 
abrogate the anti-myeloma function of BCMA CAR T cells.  
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1. Substantial Expression of BCMA on Myeloma Cells and 
Generation of BCMA CAR T Cells  
 
1.1.  BCMA expression on myeloma cells 
We first evaluated B-cell maturation antigen (BCMA) as a target for immunotherapy. 
For this purpose, the BCMA expression level on malignant plasma cells from newly 
diagnosed and relapsed/refractory MM patients were evaluated by flow cytometry.  
 
Figure 33: BCMA expression on plasma cells from MM patients. 
Plots diagram shows BCMA expression as delta mean fluorescence intensity (MFI) of 
malignant plasma cells from MM patients by flow cytometry (n=15). Histograms display 
BCMA expression in representative cases showing high, intermediate and low expression. 
Shaded histograms show staining with anti-BCMA mAb, white histogram shows staining with 
isotype control antibody. 7AAD was used to exclude dead cells from analysis. 
 
The 60% of the patients (9/15) showed a significant expression of BCMA on myeloma 
cells detected by flow cytometry. We next analyzed the BCMA expression on different 
tumor cell lines. For that, cell lines were stained with anti-BCMA mAb and analyzed 
by flow cytometry (Figure 34). All three MM cell lines (MM1.S, OPM-2 and H929) 
show considerable expression of BCMA. In order to study the functional potency of 
BCMA CAR T cells, we additionally generated BCMA-expressing K562 cells by 
transducing them with BCMA-encoding plasmid (Figure 34).  
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Figure 34: BCMA expression on MM cell lines. 
Tumor cells were gated on GFP+CD138+ cells. Histograms display BCMA expression. Blue 
histograms show staining with anti-BCMA mAb, grey histogram shows staining with isotype 
control antibody. 7AAD was used to exclude dead cells from analysis. 
 
1.2. BCMA expression on non-myeloma cells 
Importantly, we analyzed the expression of BCMA on primary CD34+ hematopoietic 
stem cells (HSC) from a healthy donor by flow cytometry. CD34+ HSC lacked cell-
surface BCMA expression (Figure 35). 
 
Figure 35: BCMA expression on human HSC. 
Human HSC from healthy donors were stained with anti-CD38, anti-CD34 and anti-BCMA 
mAbs. An isotype control antibody IgG2a,ϰ was used. Cells were analyzed by flow cytometry. 
 
 
We also evaluated in silico the antigen’s expression pattern in normal tissues using 
The Human Protein Atlas (http://www.proteinatlas.org). The RNA expression of BCMA 
in the myeloma samples is dramatically higher than the expression of any other 
tissue (e.g. brain, endocrine tissues, muscle tissues, lung, liver, pancreas, skin, 
adipose and soft tissue). Accordingly, BCMA has a restricted RNA expression pattern 
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and is expressed on malignant plasma cells in MM patients. In conclusion, BCMA is 
an attractive target for immunotherapy due to its absent expression on essential 
normal tissues, except normal B-cells. 
 
1.3.  CAR design: 2º generation CAR with 4-1BB costimulatory domain 
Due to the expression pattern of BCMA, we reasoned that BCMA would be an 
appropriate target for CAR T cells in MM. To further evaluate the suitability of BCMA 
as a therapeutic target for CAR T cells, we designed two CARs. Each CAR contained 
a single chain variable fragments (scFv) derived from one of two humanized anti-
human-BCMA monoclonal antibodies (BCMA 30 and BCMA 50) in VL-VH 
configuration. Several studies have suggested the importance to tailor the 
extracellular spacer domain for different target molecules (Hudecek et al., 2015). 
Thereby, we constructed two versions of each BCMA CAR. The short version 
consisting of the IgG4 hinge domain (12 AA, short spacer) and the long version 
contains the IgG4 hinge-CH2-CH3 domain (229 AA, long spacer). Construction of the 
long 4/2 spacer CAR was accomplished by replacing the first six amino acids of the 
CH2 domain of IgG4 (APEFLG) with the corresponding five amino acids of IgG2 
(APPVA) and an additional Asn297 to Gln mutation to abrogate the adverse 
consequences of FcγR binding in vivo. Each spacer was linked to a CD28 
transmembrane domain and a signaling module composed of CD3ζ with a 
membrane-proximal 4-1BB costimulatory domain. All vectors encoded a truncated 
epidermal growth factor receptor (EGFRt) sequence downstream of the CAR linked 
by a T2A ribosomal skip element (Wang et al., 2011) The EGFRt serves as a 
transduction marker and a tool for enrichment of CAR expressing T cells. Moreover, it 
can be used for depleting CAR T cells via EGFR binding antibodies (Figure 36). 
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Figure 36: Design of lentiviral transgene inserts encoding BCMA-specific CARs.  
Two BCMA CARs with different extracellular spacer lengths were designed. The single 
chain variable fragment (scFv) was derived from two anti-human-BCMA monoclonal 
antibodies (BCMA 30 and BCMA 50 antibodies). Four different BCMA CARs were 
obtained: BCMA 30 short and long versions; BCMA 50 short and long versions. 
 
After the amplification of BCMA CAR transgenes, the sequence of each plasmid was 
verified by sequencing and enzymes-restriction digestion to detect any non-desired 
mutation. The sequencing was performed by GATC Biotech AG. The digestion was 
performed using NheI and NotI enzymes. For that, 0.5µg of each plasmid was 
digested for 1h at 37ºC. Then, digested-DNA was separated by gel electrophoresis.  
 
Figure 37: Validation of BCMA CAR short and long versions. 
Restriction digestion analysis of BCMA CARs. Lane 1, BCMA 30 short digested with NheI 
and NotI; lane 2, BCMA 50 short digested with NheI and NotI; lane 3 BCMA 30 long 
digested with NheI and NotI; lane 4, BCMA 50 long digested with NheI and NotI. lane M, 
1kb DNA ladder (NEB). The DNAs were analyzed on 1.2 % agarose gel. 
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The short versions of the two BCMA CARs (BCMA 30 short and BCMA 50 short) 
showed a band of 2,5 Kb corresponding with the CAR short transgene, whereas the 
long versions (BCMA 30 long and BCMA 50 long) were showing a band of 3,2 Kb 
corresponding with the CAR long transgene.  
 
1.4. Transduction of T cells by lentiviral gene transfer 
Once the BCMA CAR plasmids were prepared, the lentiviral vectors were produced 
using 293-T cell line. The titration of BCMA CAR lentivirus was performed in Jurkat 
cell line. An escalation dose of lentivirus vectors was used to transduce Jurkat cells. 
After 48 hours, the transduction efficiency was analyzed by flow cytometry (Figure 
38).  
 
Figure 38: Titration of BCMA CAR lentiviral vector.  
Jurkat cells were cultured at 250 x103 cells/well in 48-well plates (Costar). BCMA lentiviral 
vector of each CAR was added to the cells. After 48 hours of incubation, cells were collected 
and stained with anti-EGFR mAb. The CAR expression was detected by flow cytometry. 
 
The lentivirus titer in transforming units (TU)/mL was calculated based on the 
expression of the EGFRt transduction marker. Replication-incompetent lentiviruses 
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encoding the CARs were used to transduce human T cells. To generate BCMA CAR 
T cells, CD4+ and CD8+ T cells from PBMC of healthy donors were isolated by 
negative selection using magnetic beads (Figure 39).  
 
Figure 39: Purity of CD4+ and CD8+ cells after selection. 
CD4+ and CD8+ T cells were isolated from PBMC of healthy donors by negative selection 
using magnetic beads. Cells were stained and analyzed by flow cytometry. 7AAD was used 
for discrimination of dead/alive cells. One representative case is shown. 
 
 
The purity of CD4 and CD8 selections was >95% in all cases (n=3). Thereby, CD4+ 
and CD8+ T cells were transduced with BCMA CAR lentivirus vectors (BCMA 30 
short/ long; BCMA 50 short/long) after 24 hours of αCD3/αCD28-bead stimulation. 
The transduction efficiency was analyzed at day 8 by flow cytometry (Figure 40, n=3).  
The percentage of CAR positive (EGFRt+) T cells was 15-30% for CD4+ subset and 
7-15% for CD8+ subset. After enrichment using the EGFRt marker, the purity of 
CAR-expressing T cells was >90%. Then, T cells that were selected for EGFRt were 
expanded in an antigen-specific manner with BCMA+ feeder cells during 7 days. The 
expanded BCMA CAR T cells were analyzed at day 5 by flow cytometry (Figure 41, 
n=3). After antigen-dependent expansion, the percentage of CAR-expressing T cells 
was >90%. Importantly, BCMA CAR T cells showed stable transgene expression 
over multiple expansion cycles.  
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Figure 40: Transduction of CD4+ and CD8+ cells with BCMA CAR lentiviral vectors. 
T cells were stimulated for 24 hours and cultured at 0.5 x106 cells/well. BCMA lentiviral 
vector of each CAR was added to the cells at MOI of 5. At day 8 of transduction, cells were 
stained with anti-EGFR mAb and CAR expression was analyzed by flow cytometry. 7AAD 
was used for discrimination of dead/alive cells. One representative case is shown. 
 
Figure 41: Enrichment and antigen-dependent expansion of BCMA CAR T cells.  
CD4+ and CD8+ BCMA CAR T cells were enriched using biotin-conjugated anti-EGFR mAb 
and anti-biotin MicroBeads (Miltenyi). Cells were cultured with irradiated TM-LCL feeder cells 
at ratio effector:target 1:7. At day 5 of antigen-dependent expansion, cells were stained with 
anti-EGFR mAb and CAR expression was analyzed by flow cytometry. 7AAD was used for 
discrimination of dead/alive cells. One representative case is shown. 
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2. BCMA CAR Design Affects Anti-Myeloma Function 
While the recognition domain is critical for CAR specificity, the connecting sequence 
between the recognition domain to the transmembrane domain, can also profoundly 
affect CAR T-cell function by producing differences in the length and flexibility of the 
resulting CAR (Dotti et al., 2014). Therefore, we compare the functionality of two 
BCMA CAR versions, one with a long and one with a short spacer. For that, the 
cytolytic activity against myeloma cells was evaluated by bioluminescence. The long 
version showed higher anti-myeloma function in both BCMA CARs. Consequently, 
BCMA 30 long and BCMA 50 long CARs were selected for further analyses. 
 
 
Figure 42: Comparison between short and long versions of BCMA CAR T cells. 
CD8+ BCMA CAR T cells were co-cultured with target cells (OPM-2 and MM.1S cell lines) in 
96-well plates (Costar) at the indicated ratios. OPM-2 and MM.1S cell lines stably express 
firefly luciferase. After 4 hours, the cytotoxicity was evaluated with a bioluminescence-based 
assay.  
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3. BCMA CAR T Cells Eliminate Myeloma Cells in Vitro  
 
3.1.  Cytotoxic activity of BCMA CAR T cells 
The next aim was to further analyze the functionality of BCMA 30 and 50 long CARs. 
We first evaluated the cytolytic activity of BCMA CAR modified and control 
untransduced T cells against BCMA+ tumor cells. For that, CD8+ T cells from three 
different healthy donors were genetically modified to express the BCMA CARs and 
their cytotoxic capability was analyzed against antigen-specific targets (Figure 43). 
Both BCMA CAR T cells showed specific killing of BCMA+ MM cell lines, without 
unspecific effect on the BCMA- control cell line (K562).  
 
Figure 43: Specific cytolytic activity of CD8+ BCMA CAR T cells. 
CD8+ BCMA CAR T cells were co-cultured with BCMA-expressing target cells, which stably 
express firefly luciferase. 4 hours later the cytotoxicity was evaluated with a 
bioluminescence-based assay. Right diagram shows specific lysis of K562/BCMA target cells 
(E:T=10:1) by BCMA CAR T cells prepared from n=3 different donors. P values between the 
indicated groups were calculated using paired Student t tests. Mock: no lentiviral vector. 
 
3.2. Cytokine production of BCMA CAR T cells 
Further, we analyzed the INF-γ and IL-2 release when CD4+ and CD8+ BCMA CARs 
were co-cultured with myeloma cell lines and K562/BCMA cell line. After 20 hours, 
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the supernatant was collected and the cytokines concentration was measured by 
ELISA (Figure 44). 
 
 
Figure 44: Cytokine production of CD8+ and CD4+ BCMA CAR T cells. 
BCMA CAR T cells were co-cultured with target cells for 24 hours. IFN-γ and IL-2 levels in 
supernatants were measured by ELISA (stimulation performed in triplicates). Data show 
mean values ± SD of one representative experiment. Mock: no lentiviral vector. 
 
Quantitative cytokine analysis showed that both BCMA CAR T cells (BCMA 30 and 
50 long) produce INF-γ and IL-2 release when they were co-cultured with target-
specific myeloma cell lines, while they did not produce cytokines release when they 
were co-cultured with the control K562 cell line. 
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3.3. Proliferation of BCMA CAR T cells 
We next analyzed the proliferation capacity of BCMA CAR T cells. Therefore, co-
cultures between CFSE-labeled BCMA 30 and 50 long CAR T cells with BCMA-
expressing target cells were performed. After 72 hours, the BCMA CAR T cells 
proliferation was measured by flow cytometry (Figure 45). 
 
Figure 45: Proliferation of CD8+ and CD4+ BCMA CAR T cells. 
CFSE labeled BCMA CAR T cells were co-cultured with BCMA+ target cells or the BCMA 
negative K562 control cell line for 72 hours. Proliferation was assessed by CFSE dye 
dilution. No exogenous cytokines were added to the assay medium except in the control 
condition IL2 (positive proliferation control; IL2: 100 U/ml). One representative case is shown. 
Mock: no lentiviral vector.  
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The proliferation of CD4+ and CD8+ mock was only observed when cells were 
cultured in the presence of IL2, whereas BCMA 30 and 50 long CARs showed 
proliferative capacity when they were co-cultured with BCMA+ target cells (OPM-2, 
H929, MM1.S and K562/BCMA).   
 
Accordantly, the increase of the percentage of proliferating cells against K562/BCMA 
target cell was statistically significant. For that, the proliferative capacity of BCMA 
CAR T cells from three different donors was compared to the proliferation rate of the 
mock (untransduced T cells).  
 
Figure 46: Percentage of proliferating cells of CD8+ and CD4+ BCMA CAR T cells. 
CFSE labeled BCMA CAR T cells were co-cultured with K562/BCMA cells during 72 hours. 
The percentage of proliferating cells (i.e. CFSE+ cells) was calculated from data obtained in 
n=3 independent experiments using FlowJo software. Data show mean values ± SD. P 
values between the indicated groups were calculated using paired Student t tests. Mock: no 
lentiviral vector. 
 
Collectively, our data demonstrate that both BCMA CARs are specific and 
functionally effective against myeloma cells. BCMA 30 and 50 long bind the same 
epitope of BCMA protein and show cytolytic activity, INF-γ and IL-2 release and 
proliferative capacity against myeloma cells.  
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4. The Serum of Multiple Myeloma Patients Contains a Soluble 
Form of BCMA Which Is Correlated with Disease Status 
The presence of soluble antigens would be a potential limitation for the clinical 
application of CARs. Thus, in addition to CAR affinity, the function can be also 
affected by soluble proteins (Cartellieri et al., 2010). We next sought to determine 
whether the myeloma cell lines release soluble BCMA (sBCMA) protein. Therefore, 
several cell lines were cultured for 24 hours and supernatant was analyzed by ELISA 
(Figure 47)  
 
Figure 47: Soluble BCMA concentration in the supernatant of cell lines. 
Cell lines were cultured at 1x106/well for 24 hours. After incubation, supernatant was 
collected and diluted at the indicated dilutions. The concentration of soluble BCMA was 
analyzed by ELISA (stimulation performed in triplicates). K562 and Jurkat cell lines were 
used as negative control. Data show mean values ± SD. 
 
Interestingly, BCMA+ cell lines including myeloma cell lines showed sBCMA in the 
supernatant indicating that BCMA-expressing cell lines are able to release sBCMA 
protein within 24 hours of culturing period. BCMA- cell lines like K562 and Jurkat did 
Strategies to Obtain Tumor-reactive Cells                              
 
 
 
 
148 
not show sBCMA released. The transduced cell line K562/BCMA expressed the 
highest concentration of sBCMA.  
Moreover, we investigated whether the serum from MM patients contains sBCMA. 
For that, peripheral blood from MM patients was centrifuged and the serum was 
collected and analyzed by ELISA for sBCMA concentration (Figure 48). 
 
Figure 48: Soluble BCMA concentration in the serum of MM patients. 
Peripheral blood from MM patients was collected. Centrifugation at 3.000 rpm for 10 
min was performed to obtain patient’s serum. The serum was diluted at the indicated 
dilutions. The concentration of soluble BCMA was analyzed by ELISA (stimulation performed 
in triplicates). Medium without serum was used as negative control. Data show mean values 
± SD. PD, progressive disease; SD, stable disease; PR, partial remission; CR, complete 
remission. 
 
The concentration of sBCMA was higher in patients with progressive disease as 
compared to the sBCMA level on complete remission patients suggesting that soluble 
form of BCMA is correlated positively with disease burden. 
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5. Soluble BCMA Does Not Abrogate the Efficacy of BCMA CAR T 
Cells 
 
5.1.  Cytotoxic activity of BCMA CAR T cells in the presence of sBCMA  
We next sought to determine whether the presence of sBCMA could affect the 
functionality of BCMA CAR T cells. In order to assess the influence of sBCMA on 
cytolytic activity. CD8+ BCMA CAR T cells were co-cultured with target cells in 
different effector:target ratio in the presence or absence of sBCMA protein. The 
specific lysis was measured at 4 hours.  
 
Figure 49: Specific cytolytic activity of CD8+BCMA CAR T cells in presence of sBCMA. 
CD8+ BCMA CAR T cells were co-cultured with MM1.S and K562/BCMA target cells in 
absence (continuous line) or presence (discontinuous line) of 150 ng/ml of soluble BCMA. 
After 4 hours, luciferin was added to the culture and the cytotoxicity was evaluated with a 
bioluminescence-based assay. Data show mean values ± SD. 
 
The cytolytic activity of both BCMA CARs against tumor cell lines in presence of 
sBCMA vs. fresh medium was similar suggesting that sBCMA protein is not 
interfering with the cytotoxic function of BCMA CAR T cells.  
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5.2. Activation of BCMA CAR T cells in the presence of sBCMA  
Further, we were interested to analyze the percentage of activated BCMA CAR T 
cells in the presence of sBCMA to determine whether the soluble form of the protein 
could load the aggregation of BCMA CARs. Thus, cultures of CD4+ and CD8+ BCMA 
CAR T cells were performed using an increasing dose of sBCMA and the percentage 
of CD69+/CD25+ cells was analyzed by flow cytometry (Figure 50) 
 
Figure 50: Percentage of activated cells of BCMA CAR T cells in presence of sBCMA. 
BCMA CAR T cells were incubated with soluble BCMA protein at the indicated 
concentrations for 24 hours. No target cells were added to the assay. P/I condition: PMA (25 
ng/ml) and Ionomycin (1 μg/ml) were added to the culture. The percentage of activated T 
cells (CD25+CD69+) was calculated from data obtained in n=2 independent experiments 
using FlowJo software. Data show mean values ± SD. Mock: no lentiviral vector. 
 
No differences in the percentage of activated CD69+/CD25+ T cells were observed 
when BCMA CAR T cells were cultured with or without sBCMA. Moreover, as 
indication of cell activation, we investigated the INF-γ release when BCMA CAR T 
cells were cultured with an increasing dose of sBCMA. The supernatant was 
collected after 24 hours and analyzed by ELISA (Figure 51). Concordantly, the INFγ 
secretion was similar when BCMA CAR T cells were cultured with or without sBCMA. 
In aggregate, these results suggest that sBCMA does not interfere with BCMA 30 
and 50 CAR T cells neither abrogating the cytotoxicity activity nor inadvertent T-cell 
activation with cytokine release due to aggregation of BCMA CARs.  
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Figure 51: INF gamma secretion of BCMA CAR T cells in presence of sBCMA. 
BCMA CAR T cells were incubated with soluble BCMA protein at the indicated 
concentrations for 24 hours. No target cells were added to the assay. P/I condition: PMA (25 
ng/ml) and Ionomycin (1 μg/ml) were added to the culture. IFN-γ level in supernatants was 
measured by ELISA (stimulation performed in triplicates). Diagrams show the concentration 
of INF-γ calculated from data obtained in n=2 independent experiments. Data show mean 
values ± SD. Mock: no lentiviral vector. 
 
 
5.3. sBCMA protein detection  
Finally, we performed western blot analyses of K562 and K562/BCMA cells and their 
supernatant to determine whether the target epitope of sBCMA protein is hidden so 
that BCMA CARs are not affected. 
 
Figure 52: Western blot analysis of soluble and membrane BCMA.  
K562 and K562/BCMA cell lines were cultured at 1x106/ ml for 24 hours. A) and C) The 
supernatant was concentrated in soluble BCMA using Vivaspin tubes (Sartorius). B) Cells 
were harvested and treated with RIPA buffer. A 4-20% polyacrylamide gel was used. 
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A band of 6 kDa was observed when supernatant of K562/BCMA was analyzed in 
reducing condition. This band corresponds in size to the soluble BCMA protein. 
However, a 20 kDa band was visualized when K562/BCMA cells were analyzed 
corresponding with the membrane BCMA. Interestingly, when the supernatant of 
K562/BCMA was analyzed in non-reducing condition (the secondary structure is 
maintained), a ≈12 kDa band was observed suggesting that sBCMA could form 
dimers. Altogether, these results indicate that the efficacy of BCMA CAR T cells is 
not affected by the presence of soluble BCMA protein probably due to the non-
accessibility of the BCMA CAR to the target epitope of the protein. 
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6. BCMA CAR T Cells Eradicate Tumor in Vivo 
Finally, we analyzed anti-tumor efficacy of generated BCMA CAR T cells in a 
systemic BCMA+ multiple myeloma xenograft model (NSG/MM1.S-ffLuc) (Figure 53).  
 
  
 
  
Figure 53. In vivo antitumor reactivity of BCMA CAR T cells.  
A) NSG mice were inoculated with MM1.S-ffluc/eGFP cells and 14 days later treated with 
5x106 BCMA CAR T cells (1:1 ratio of CD8+ and CD4+ T cells, 2.5x106 each) or unmodified 
control T cells (mock). BCMA CAR T cells were generated by lentivirus transduction. 
Bioluminescence images were obtained on day 14 (before T-cell infusion, upper row), on day 
21 (7 days after T-cell infusion, middle row) and on day 41 (27 days after T-cell infusion, 
lower row). B) Kaplan-Meier analysis of survival in groups of mice treated with BCMA CAR 
30 T cells (n=4), BCMA CAR 50 T cells (n=4) and mock T cells (n=4). C) Bar diagram shows 
the relative difference in Avg Radiance (%) of each mouse. The relative difference was 
calculated as follows: [(Avg Radiance on day 21- Avg Radiance on day 14) / Avg Radiance 
on day 21]*100. 
 
A 
B C 
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A potent anti-tumor effect was mediated by a single dose of CD8+ and CD4+ BCMA 
CAR T cells. These cells rapidly eradicated myeloma cells in all treated mice (n=4), 
whereas the mice receiving control T cells showed progressive, deleterious myeloma 
(Figure 53A). 
Relative difference in average radiance was calculated between day 21 (7 days after 
T cells infusion) and day 14 (before T cells infusion, already established tumor). As 
shown in Figure 53C, infusion of BCMA CAR 30 and 50 T cells dramatically reduce 
the tumor burden compared to control T cells (>6000 units of difference). 
Collectively, our data demonstrate that BCMA CAR engineered-T cells are highly 
potent in vitro and in vivo. Hence, we were able to redirect T cells against the tumor-
specific antigen BCMA by CAR Technology and successfully trigger multiple 
myeloma disease. 
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7. Interim Conclusion for CAR Technology 
As the second objective of this study we aimed to create a second generation CAR 
against the B-Cell Maturation Antigen (BCMA) by genetic modification of T cells and 
to confirm their anti-tumor reactivity against myeloma cells to treat multiple myeloma 
(MM) patients.  
 
Generating tumor-specific CTLs ex vivo may address some difficulties associated 
with the isolation and use of conventional strategies to obtain them, such as cytokine 
production assay or soluble pMHC multimers: 1) pMHC multimers can often fail to 
stain antigen specific T cells where the interaction between pMHC and TCR is weak. 
2) Reproducible results in the clinic with the use of these approaches is often hard to 
achieve based on the variability between patients. We hypothesized that gene 
transfer could be exploited to redirect T cells against tumor specific antigens 
expressed on the surface of tumor cells by introducing transgenes that encoded 
chimeric antigen receptors (CAR). Hence, the generation of CAR T cells may solve 
these problems due to the use of different antibodies affinities and the possibility to 
select desired subsets of T cells from the patients. 
 
Collectively, we have designed and developed several BCMA CARs to trigger 
myeloma cells. Further, we have observed that the long spacer confers higher anti-
myeloma function than the short one. BCMA CAR T cells showed specific cytolytic 
activity, production of cytokines including IFN-γ and IL-2, as well as productive 
proliferation against BCMA-expressing target cells. Moreover, we have confirmed the 
presence of soluble BCMA in the serum of MM patients. We also demonstrated that 
the presence of soluble BCMA does not abrogate the efficacy of BCMA CAR T cells 
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suggesting that BCMA CARs can be used in the clinical setting to trigger multiple 
myeloma disease. Furthermore, different subsets of T cells like CD4 and CD8 can be 
successfully engineered against BCMA by gene transfer and those subsets show an 
appropriate and significant efficacy. Hence, our data indicate the great advantage of 
CAR Technology to trigger tumor-specific antigens in order to efficiently eradicate the 
tumor. 
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1. “Doublet Technology” to Obtain Tumor-reactive T Cells from 
Acute Myeloid Leukemia Patients 
Harnessing the immune system to recognize and destroy tumor cells has been the 
central goal of anti-cancer immunotherapy. Currently, there is an increasing interest 
to optimize anti-tumor technologies in order to develop clinically feasible therapeutic 
approaches. One of the main treatment modalities in cancer immunotherapy is based 
on adoptive transfer of T cells (ACT). Using this approach, tumor-specific cytotoxic T 
cells (CTLs) are infused into cancer patients with the goal of recognizing, targeting, 
and destroying tumor cells (Perica et al., 2015). T lymphocytes are multifunctional 
effector cells with exquisite antigen specificity and with a clear biologic role in the 
defense of the organism. The importance of T cells in the control of malignancy is 
inferred from studies showing increased susceptibility to neoplasia in 
immunodeficient patients or experimental animal models, and from decades of 
experience with allogeneic bone marrow transplantation that have established the 
central role of T cells in the ‘‘graft-versus-tumor’’ response (Gill and Kalos, 2013). 
The conventional methods to obtain tumor-specific CTLs are cytokine production 
assays and soluble pMHC multimers (Becker et al., 2001; Savage et al., 2007). The 
first one is based on selecting those CTLs that highly release INF-γ. However, 
cytokine-producing T cells are not necessarily cytotoxic, so that they would not 
present the capacity to destroy target cells. Furthermore, we should take in 
consideration the “bystander effect” which is antigen non-specific stimulation due to 
some T cells could release INF-γ not because they are tumor-reactive cells, but 
because they are stimulated through cytokines released from bystander lymphocytes 
(Panelli et al., 2000; Snyder et al., 2003; Boyman, 2010). Prior work showed that IFN-
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γ secretion and cytotoxic ability are regulated independently. Thus, the secretion of 
IFN-γ without killing by some CD8+ T cells was confirmed by combining the Lysispot 
with an IFNγ Elispot in a two-color assay (Snyder et al., 2003). On the other hand, 
the use of soluble pMHC multimers consist of multiple pMHC complexes that have 
been chemically linked together and conjugated to a detectable marker (Wooldridge 
et al., 2009). Although, this technology has been successfully used (Cobbold et al., 
2005; Savage et al., 2007), there are several obstacles that need to be solved. For 
example, the binding affinity threshold for pMHC class I (pMHC-I) tetramers is 
significantly higher than that required for T cell activation. As a result, pMHC-I 
tetramers cannot be used to detect all antigen-specific CD8+ T cells (Wooldridge et 
al., 2009; Dolton et al., 2014). Moreover, pMHC multimers can fail for isolation of 
antigen-specific CD4+ T cells due to the lower affinity of pMHC-II tetramers (Hackett 
and Sharma, 2002; Wooldridge et al., 2009). In this study, we show for the first time 
the feasibility to isolate of tumor-specific CTLs from acute myeloid leukemia (AML) 
patients. First, we have analyzed the dynamics of various binary complexes (pHLA), 
and their corresponding ternary ones (pHLA-TCR), with a different degree of immune 
reactivity in order to clarify the interaction of pHLA and TCR at the molecular level. 
The TAX/HLA-A0201/TCR-A6 was chosen as a model system because it has been 
extensively studied experimentally. Ding et al. were one of the first groups to study 
these peptides in the context of different T cell signals. They calculated the binding 
thermodynamics of three structures of HLA-A2/TCR-A6 complexes containing singly 
substituted variants of the reactive TAX peptide of the human T cell lymphotropic 
virus HTLV-1, which is known to cause adult T-cell leukemia/lymphoma. Their work 
provided direct evidence that the capacity of variant TAX peptides (V7R, P6A and 
Y8A) to produce different biological effects upon interaction with the TCR-A6 is 
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correlated with the strength of the interaction pMHC-TCR (Ding et al., 1998; Ding et 
al., 1999). T cell assays demonstrated that TAX peptide induces specific lysis, 
secretion of INF-γ and macrophage inflammatory protein 1β (MIP-1β), while P6A and 
Y8A peptides do not. The complex between TAX-HLA and TCR shows a low 
dissociation constant and V7R-TAX shows a ten-fold decrease in the affinity and, 
finally, P6A and Y8A complexes are too weak to be analyzed by biophysical methods 
suggesting that long pMHC-TCR half-lives correlate tightly with agonist signals that 
induces T cell activation. Our data demonstrate that pHLA-TCR interactions that 
involve reactive peptides are more stable and strong compared to non-reactive 
interactions. As shown in section 1 (Part I) molecular dynamics enable us to discern 
patterns of salt bridges, in pHLA and pHLA-TCR complexes that differ according to 
the reactivity of the complex. Thus, we note a significant loss of salt bridges in the 
non-reactive ternary complexes relative to the reactive complex: reactive complex 
TAX-HLA-TCR (13 salt bridges) > intermediate complex V7R-HLA-TCR (10 salt 
bridges) > non-reactive complexes P6A-HLA-TCR and Y8A-HLA-TCR (5 and 7 salt 
bridges, respectively). This may explain why the interaction between HLA and TCR is 
weaker in non-reactive complexes than in the reactive ones. Taking this data into 
consideration, we sought to take advantage of this stable and strong interaction and 
isolate tumor-specific CTLs through FACS-based cell sorting. In fact, we observe that 
when T cells from AML patients are co-cultured with tumor cells, doublet population 
appears. This population consists of T cells bound with strong interactions to tumor 
cells. Following the sorting strategy explained in material and methods (section 4.4), 
we were able to isolate tumor-specific CTLs from AML patients. These AML-specific 
CTLs have shown cytolytic activity against primary blast cells suggesting the potential 
use of these CTLs in the clinical setting. Further, not only CD8+ tumor-reactive T 
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cells are isolated with this approach, but also CD4+ effector T cells. Although CD4+ T 
cells are classically viewed as helper cells facilitating CD8+ T cell function, it is now 
clear that both cell subsets can exert cytotoxicity against tumor targets (Restifo et al., 
2012; Bollard and Barrett, 2014). Moreover, we have demonstrated that selecting 
doublet-forming T cells, we are depleting regulatory T cells with immune suppressive 
function from the pool of patient´s T cells. Altogether, “Doublet Technology” allows us 
to identify and isolate tumor-specific T cells from patients diagnosed with hematologic 
malignancies and warrant further studies to investigate the safety and efficacy of this 
new strategy to treat hematologic malignancies. 
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2. CAR Technology to Generate Tumor-reactive T cells from 
Multiple Myeloma Patients 
The abilities of T cells to coordinate immunity and to deliver lethal hits against 
diseased cells can be directed towards tumors by genetically modifying T cells. 
Genes encoding tumor specific antigens can be inserted into T cells to enable them 
to recognize and respond to cancer cells. CAR technology may solve the problems 
that conventional approaches for obtaining tumor-specific T cells present. In this 
study, we create a second generation CAR against the tumor B-Cell Maturation 
Antigen (BCMA) by genetic modification of T cells to treat multiple myeloma (MM) 
patients. A critical factor for any antigen being considered as a target for 
immunotherapies is the expression pattern of the antigen in normal tissues. 
Therefore, we first confirmed the expression of BCMA on malignant cells of myeloma 
patients and on myeloma cell lines and verified the absence of BCMA expression on 
hematopoietic stem cells (HSC), in agreement with other works (Laabi et al., 1992; 
Novak et al., 2004). We designed CARs with different recognition domains targeting 
the same BCMA epitope. Each of these CAR constructs was tested as two different 
versions (short and long) to study the effect of the CAR design in the functionality. 
Several studies have already suggested the importance to tailor the extracellular 
spacer domain of every CAR individually for different target molecules and epitopes 
(Hudecek et al., 2015). While the recognition domain is critical for CAR specificity, the 
connecting sequence between the recognition domain and the transmembrane 
domain (the hinge region), can also profoundly affect CAR T-cell function by 
producing differences in the length and flexibility of the resulting CAR (Dotti et al., 
2014). A study of CD22-specific CARs suggested that the distance of the target 
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epitope from the cell membrane plays an important role in CAR design (Haso et al., 
2013). This theory is supported by the observation that tumor recognition by 5T4- and 
NCAM-specific CARs that recognize membrane-proximal epitopes was improved with 
a long spacer (Guest et al., 2005). Therefore, we tested two different versions of the 
hinge region, one short version consisting of the IgG4 hinge domain (12 AA, short 
spacer) and one long version containing the IgG4 hinge-CH2-CH3 domain (229 AA, 
long spacer). We could find that our BCMA-specific CARs showed more potent and 
efficient killing of myeloma cells when they were designed with the long spacer. This 
result matches with the fact that BCMA-CARs recognize a membrane-proximal 
epitope (24 - 41 AA) of the extracellular domain of BCMA. In addition, the 
extracellular domain of BCMA is very short (54 AA) compared to others proteins 
(CD19: 272 AA; CD20: 668 AA) so that the long spacer of BCMA CAR offers better 
flexibility to access the target. One further important point in the design of a CAR is 
the costimulatory domain. Although both CD28 and 41BB costimulatory domains 
augment cytokine secretion compared to first-generation CARs, several studies have 
already shown that the incorporation of 4-1BB signaling domain in second-generation 
CARs prevent anergy and promote T cell proliferation and memory, with the 
anticipation of a greater effect on T cell maintenance than on functional activation 
compared to CD28 (Kalos et al., 2011; van der Stegen et al., 2015; Kawalekar et al., 
2016). Hence, we incorporated the 4-1BB costimulatory domain into BCMA CARs. 
The functional tests show that T cells expressing BCMA 30 and 50 CARs designed 
with a long spacer have potent antitumor effect against myeloma cell lines, show 
antigen-specific INF-γ and IL-2 release as well as proliferative capacity. Our BCMA 
CARs were compared to a recently published BCMA CAR (Ali et al., 2016) and they 
present similar cytolytic activity, cytokine production and proliferation in vitro (data not 
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shown). The presence of soluble target protein in the serum of MM patients promotes 
controversial issues due to the possibility to abrogate the functionality of CARs. 
Therefore, we analyzed the serum of MM patients to study the presence of soluble 
BCMA (sBCMA) protein. Soluble BCMA was detected and, in fact, it did correlate 
with disease status. Thus, serum BCMA levels are higher among patients with 
progressive disease as compared to those with responsive disease confirming a 
correlation between sBCMA concentration and disease burden. This conclusion is in 
agreement with the previous report by Sanchez et al. (Sanchez et al., 2012). In 
addition to CAR affinity, function can be also affected by soluble antigen proteins 
(Cartellieri et al., 2010). Hence, we determined whether the sBCMA could abrogate 
the anti-myeloma function of BCMA CAR T cells using a synthetic sBCMA protein 
and/or supernatant containing released sBCMA. Cytotoxic activity in the presence of 
high concentration of sBCMA (150 ng/ml, which is 10x more than the concentration 
observed in patients with progressive disease) shows that soluble protein does not 
abrogate the cytolytic function of BCMA CARs. We also consider the hypothesis that 
sBCMA could aggregate BCMA CAR T cells triggering unspecific CAR activation. 
Thus, CD69+CD25+ T cells and INF-γ release were analyzed in the presence of 
increasing amount of sBCMA and without antigen-specific target cells. No activation 
of BCMA CAR T cells or INF- γ release were detected even at the highest amount of 
sBCMA (150 ng/ml) suggesting that sBCMA does not interfere with BCMA CAR T 
cells in vitro. One possible explanation for these results is that sBCMA is part of 
homodimeric or heterodimeric complexes so that the target epitope of the soluble 
protein is not accessible. sBCMA has a molecular weight (MW) of ≈6 kDa 
demonstrated by western blot analysis. This is consistent with the previous report by 
Laurent et al. (Laurent et al., 2015). Non-reducing western blot analyses also 
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revealed ≈12 kDa band suggesting that sBCMA can form homodimeric complexes. In 
this regard, it has been already reported that sBCMA can form large complexes with 
APRIL (a proliferation-inducing ligand, (Hymowitz et al., 2005) and BAFF (B-cell 
activating factor, (Liu et al., 2003) supporting the idea that the target epitope of 
sBCMA could be hidden so that the functionality of BCMA CARs is not affected.  This 
fact is also seen in other CARs. In vitro studies have shown that anti-
carcinoembryonic antigen (anti-CEA) CARs are not inhibited by soluble CEA, even at 
high concentrations (Hombach et al., 1999; Gilham et al., 2002). Finally, we 
developed a systemic BCMA+ myeloma xenograft model (NSG/MM1.S-ffluc) to study 
the BCMA CARs function in vivo. A potent antitumor effect was mediated by a single 
dose of BCMA CAR T cells. Collectively, we are able to generate BCMA CARs that 
eradicate myeloma cells in vitro and in vivo and warrant clinical trials to investigate 
the safety and efficacy of this approach to treat MM patients.  
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3. Clinical Translation  
Adoptive transfer of tumor-reactive cytotoxic T cells is a promising therapeutic 
approach for cancer treatment. To develop this strategy, it is necessary to obtain 
tumor cytotoxic T lymphocytes (CTLs) that will be reinfused into the patient after 
expansion in vitro. Here, we present two strategies to obtain tumor-specific T cells.  
“Doublet Technology” is a personalized therapy. With this technique, we can obtain 
tumor-specific T cells from hematologic patients, being the equivalent of TIL in solid 
tumor. The protocol starts obtaining tumor cells from patients either at diagnosed or 
after relapse and freezing down. After chemotherapy regimens and when the patient 
achieves the complete remission status, peripheral blood is extracted. Once the co-
culture between PBMC and tumor cells is performed, tumor-specific T cells can be 
sorted in 15 hours. Those T cells have the advantage that they are already cytotoxic 
tumor-specific T cells so that they can be directly and rapidly expanded with IL2 or 
soluble anti-CD3/anti-CD28 without a selection step like measure of INF-γ, which is 
usually needed in TIL therapy (Restifo et al., 2012). Therefore, “Doublet Technology” 
is a fast, cost-effective approach to obtain tumor-reactive T cells. The principal 
advantage of this strategy is that there is no need for a priori knowledge of exact 
tumor antigen, emphasizing the broadly applicability of this technology. Moreover, 
we isolate not only CD8+ tumor-reactive T cells, but also CD4+ tumor-reactive T 
cells, which are also important in tumor eradication (Restifo et al., 2012; Bollard and 
Barrett, 2014). One disadvantage is the variability between patients, but this is an 
assumed factor in cell therapies. Recently, the existence of marrow-infiltrating 
lymphocytes (MIL) and their use in MM patients has been reported, supporting our 
approach for tumor-specific T cell sorting. In fact, “Doublet Technology” presents the 
advantage to obtain tumor-specific CTLs from peripheral blood, without bone marrow 
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aspiration surgery which might also be a potential source of CTL using our 
technology. Several works have reported that the bone marrow is a reservoir for 
regulatory T cells (Tregs) (Zou et al., 2004). Taking this result in consideration and 
combine with the fact that we are able to deplete Tregs from the pool of tumor-
specific T cells, “Doublet technology” is presented as a safe strategy.  
CAR T-cell Therapy is a transformative novel way for treating advanced 
malignancies. In fact, CAR Therapy has been reached successful results in 
hematologic malignancies. The clinical protocol is the standard in gene-modified 
therapies (Turtle et al., 2012). The principal advantage of this strategy is the 
specificity. Compared with natural TCRs, CARs have several orders of magnitude 
higher affinities to target antigens that make them more potent in tumor eradication 
(Harris and Kranz, 2016). In addition, CARs recognize intact cell surface proteins in 
an MHC-independent manner, so that they are insensitive to tumor escape 
mechanisms related to MHC loss variants. Compared to “Doublet Technology”, CAR 
Therapy presents higher reproducibility; however, it is necessary to know the tumor 
antigen a priori. Moreover, with this strategy we are able to select the specific subset 
of T cells which would be engineered and infused into the patient. In this study, we 
used CARs targeting the BCMA antigen. BCMA is expressed on malignant plasma 
cells in MM and is an attractive target for immunotherapy due to its absent 
expression on normal tissues, except normal B-cells. Thus, low on-target off-tumor 
toxicity should be expected. Finally, therapeutically relevant CAR T-cell numbers 
could be obtained for the clinical setting with our CAR-based approach. 
In conclusion, our developed strategies pave the way for broader and advanced 
clinical application of T-cell therapies for the treatment of hematologic malignancies. 
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4. Final remarks and Further Work  
“Doublet technology” is a new procedure to obtain tumor-specific T cells for clinical 
implementation in cancer immunotherapy. There is no need for a priori knowledge of 
exact tumor antigen, emphasizing the broadly applicability of this technology. 
However, the identification of new tumor antigens is needed for the development of 
therapeutic strategies against cancer. Thus, we could sequence and clone the region 
CDR3 of the tumor-reactive CTLs isolated and, through a mathematical model, to 
identify the antigens or groups of antigens against which the cytotoxic antitumor 
response is generated, using the following databases: Basic Local Alignment Search 
Tool (BLAST), ImMunoGeneTics (IMGT) and The ExPASy (Expert Protein Analysis 
System). Moreover, TCR sequence of these natural tumor-reactive CTLs can be 
used to redirect lymphocyte specificity to cancer antigens by genetic engineering. 
 
CAR T cell therapy is a highly innovative and very potent new modality for treating 
advanced malignancies. However, it has been documented that targeting a single 
antigen on tumor cells with CAR T cells may lead to the selection and outgrowth of 
tumor cells that have learnt to lose that antigen (antigen-loss as escape mechanism). 
This phenomenon has in fact been described in a clinical trial where myeloma has 
been treated with CAR T cells directed against the BCMA antigen alone (Ali et al., 
2016). To reduce the risk of antigen loss, we could explore the concomitant targeting 
of two myeloma-specific antigens (CS1 and BCMA) and investigate whether 
simultaneous targeting of these two antigens is advantageous compared to targeting 
each antigen alone.  
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“Doublet Technology” 
1. pHLA-TCR interactions that involve immune reactive complexes are more stable 
and strong as compared to those which do not induce immune activation.  
2. The complex T cell-tumor cell occurs at sufficient frequency and shows enough 
functional avidity that can be isolated by FACS-based cell sorting. 
3. Tumor-reactive T cells from AML patients can be identified and isolated based on 
their capability to form stable and strong interactions through TCR with tumor 
cells.  
4. The CTLs from AML patients obtained with “Doublet Technology” show cytolytic 
activity against blast cells.  
5. Using this approach, there is no need to know a priori the exact tumor antigen; 
therefore, we might be able to obtain tumor-specific T cells from each patient 
offering a personalized therapy. 
 
CAR Technology 
1. BCMA is highly expressed on myeloma cells and T cells can be genetically 
modified with BCMA-specific CARs. 
2. A long spacer domain confers higher anti-myeloma function to BCMA CARs.  
3. BCMA CAR T cells show antigen-specific cytolytic activity, production of 
cytokines, as well as productive proliferation against myeloma cells.  
4. Serum from MM patients contains soluble BCMA protein.  
5. Soluble BCMA does not abrogate the efficacy of BCMA CAR T cells indicating 
the potential use of these T cells in the clinical setting. 
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“Tecnología de Dobletes” 
1. Las interacciones pHLA-TCR que implican complejos inmuno-reactivos son más 
estables y fuertes comparados con aquellos que no inducen activación inmune. 
2. El complejo célula T-célula tumoral se produce con suficiente frecuencia y 
presenta la estabilidad suficiente como para permitir identificar y seleccionar 
dicho complejo mediante separación celular. 
3. Las células T anti-tumorales de pacientes con LMA pueden ser identificadas y 
aisladas por su capacidad de formar fuertes y estables interacciones con células 
tumorales a través de TCR.  
4. Los CTLs de pacientes con LMA obtenidos con la “Tecnología de Dobletes” 
muestran actividad citolítica frente a blastos del mismo paciente. 
5. Mediante este enfoque, no es necesario conocer a priori el antígeno tumoral; por 
lo que podríamos ser capaces de obtener células T anti-tumorales de cada 
paciente ofreciendo así una terapia personalizada. 
Tecnología CAR 
1. El antígeno BCMA está altamente expresado en células de mieloma y las células 
T pueden ser genéticamente modificadas con CARs dirigidos frente a BCMA. 
2. La versión “long” confiere mayor función anti-tumoral a las células T BCMA CAR. 
3. Las células T BCMA CAR presentan actividad citolítica, producción de 
citoquinas, así como capacidad proliferativa frente a células de mieloma. 
4. El suero de pacientes con MM contiene proteína soluble BCMA. 
5. La proteína soluble BCMA no anula la eficacia de las células T BCMA CAR 
indicando el potencial uso de estas células T en el contexto clínico. 
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